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B‐cell  chronic  lymphocytic  leukemia  (CLL)  is  the most  common  type of  leukemia  in  the 
Western world. CLL is not curable with currently available therapies. Another neoplastic 
entity  that  shares  genotypic  and  phenotypic  characteristics  with  CLL  is  mantle  cell 
lymphoma (MCL), comprising approximately 6% of all Non‐Hodgkin lymphomas (NHL).  
MicroRNAs  (miRNAs)  are  small  single  stranded  RNA  molecules  with  a  length  of 
∼21 nucleotides, which regulate the stability and translation of protein coding messenger 
RNAs  (mRNAs).  It  is estimated  that 30% of all protein coding genes of an organism are 
regulated  by  miRNAs.  Within  recent  years,  evidence  arose  that  the  deregulated 
expression  of  miRNAs  plays  a  pivotal  role  in  cancer.  MicroRNA‐155  and  the  miR‐17‐92 
cluster  are  aberrantly  expressed  in  various  cancers  including  B‐cell  lymphomas.  The 
present  work  aimed  at  the  identification  of  transcripts  regulated  by  these  aberrantly 
expressed miRNAs.  To  this  end,  current  standard  techniques  like  quantitative  real‐time 
reverse  transcription  PCR,  luciferase  sensor  assays  and  Western  blot  analyses  were 
performed.  As  the  results  of  these  studies  revealed  only  minor  effects,  an  alternative 







the  RNA  destabilizing  protein  ZFP36.  Expression  profiling  further  revealed  significant 
changes  in  the  transcriptome  and  miRNome  as  a  consequence  of  ectopic  miR‐155 
expression.  For  instance,  the  cell  cycle  gene  CCND1  and  the  cancer  associated  ETS 
transcription  factor  sub‐family  PEA3  were  severely  up  regulated.  Using  RIP‐Seq,  the 
targetomes  of  two  B‐cell  lines  representing  CLL  and  MCL  were  identified.  These 
targetomes  comprise  more  than  1,000  target  genes  each,  with  more  than  600  genes 
shared by both cell  lines,  including  the putative  tumor suppressor gene BTG2  as one of 
the most prominent miRNA target genes. MicroRNA profiling of the immunoprecipitation 






































Die  chronische  lymphatische  Leukämie  vom  B‐Zell  Typ  (CLL)  ist  die  häufigste 
Leukämieform  der  westlichen  Welt.  CLL  ist  mit  derzeit  verfügbaren  Therapien  nicht 




Nukleotiden,  die  die  Stabilität  und  Translation  von  Protein‐kodierenden  Boten‐RNAs 
(mRNAs)  beeinflussen.  Es wird  angenommen,  dass  30%  aller  protein‐kodierenden Gene 
eines Organismus durch miRNAs reguliert werden.   Innerhalb der letzten Jahre mehrten 
sich die Hinweise, dass die abnormale Expression von miRNAs eine zentrale Rolle bei der 
Entstehung  von  Krebs  spielt.  MicroRNA‐155  und  das  miR‐17‐92  Cluster  sind  in 
verschiedenen  Krebsarten,  unter  anderem  in  B‐Zell  Lymphomen,  abnormal  exprimiert. 
Die  vorliegende  Arbeit  hatte  das  Ziel  Transkripte  zu  identifizieren,  die  durch  diese 
abnormal  exprimierten  miRNAs  reguliert  werden.  Zu  diesem  Zweck  wurden  zunächst 
Methoden wie quantitative real‐time reverse transcription PCR, Luciferasesensor Assays 
und Western blot Analysen verwendet. Da die gemessenen Effekte jedoch relativ gering 
waren,  wurde  eine  alternative  Untersuchungsmethode  etabliert.  Diese  basiert  auf  der 




zeigten  diese  Zellen  eine  erhöhte  Zellproliferation.  RIP‐Seq  Experimente  ergaben  eine 
signifikante  Anreicherung  von  67  mRNAs,  wie  zum  Beispiel  Transkripte  des 
Transkriptionsfaktors CEBPB oder das RNA destabilisierende ZFP36, die als Zieltranskripte 
von miR‐155  vorhergesagt wurden.  Bei  der Untersuchung  der  Expressionsprofile  dieser 
Zellen  zeigten  sich  signifikante  Veränderungen  im  Transkriptom  und  MiRNom  als 







1000  Zielgene,  von  denen  mehr  als  600  in  beiden  Zelllinien  identifiziert  wurden.  Ein 
herausragendes  Transkript  war  das  mögliche  Tumorsuppressorgen  BTG2.  Die  Messung 
von MikroRNAs in den IP‐ und zugehörigen total Lysat‐ (TL) Fraktionen, die durch RIP‐Seq 
generiert  wurden,  zeigten  eine  wiederholte,  disproportionale  Anreicherung  einiger 
miRNAs  in  AGO2‐IPs.  Zu  diesen  miRNAs  gehören  unter  anderem  miR‐155  und  einige 








Cancer  is  the  uncontrolled  growth  and  spread  of  cells.  It  is  the  third  most  common 
disease  leading  to  death worldwide.  The  International  Agency  for  Research  on  Cancer 
(IARC) registered 12.4 million  incidences of cancer and 7.6 million deaths from cancer  in 
2008. According to the growth and aging of the world’s population, a constant increase 
in  cancer  burden  worldwide  is  assumed.  Calculations  suggest  an  increase  of  cancer 
related deaths up to 17.0 million in the year of 2030 [1].  
According  to  the World Health Organization  (WHO), neoplastic  lesions are  classified by 
their  origin.  Solid  tumors  arising  from  the  epithelium  are  termed  carcinomas,  those 
emerging  from  the  mesenchyme  and  connective  tissues  are  termed  sarcomas  and 
malignancies  of  the  hematopoietic  and  lymphatic  system  are  termed  leukemia  or 
lymphomas,  respectively.  Most  tumors  evolve  from  a  locally  restricted  (benign)  to  an 
invasive (malignant) neoplasm, which is typically accompanied by a decreasing degree of 
cell  differentiation.  To  date  there  are more  than  100  different  cancer  types  described. 
Virtually every tissue of an organism can give rise to a neoplastic tissue.  
In  order  to  prevent  cancer,  one  of  the  first  steps  is  the  identification  of  carcinogens 
causing malignancies.  For  instance,  chemicals  like  formaldehyde,  aflatoxins  from  fungi, 
asbestos, ionizing radiation, viruses and tobacco smoke are classified as carcinogens. The 
WHO  associates  tobacco  smoke,  for  instance,  with  the  cause  of  13  different  cancers. 
Among these lung cancer is the most prominent one.  
Although cancer research has made significant progress during the past decades, a more 





the  affected  tissue.  According  to  current  knowledge,  tumorigenesis  is  a  multi  step 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process, which  seems  to  be  fairly  analogous  to  Darwinian  evolution.  Douglas  Hanahan 
and Robert A. Weinberg in 2000 proposed a model, which is trying to structure the high 
diversity  of  cancer  types  coming  along  with  a  high  complexity  with  regard  to  the 
underlying  principles  leading  to  cancer  development  [2].  They  proposed  six  hallmarks 
typically acquired by human cancers.  
Cancer  cells  sustain  their  proliferation  by  enhancing  the  release  of  mitogenic  signals, 
stimulation  of  supporting  cells  and  elevation  of  surface  receptor  levels  accepting 
mitogenic  signals.  Somatic  mutations  of  proteins  like  BRAF,  involved  in  mitogenic 
signaling circuits, were shown to be involved in carcinogenesis by increasing the activity 
of the growth promoting MAPK signaling pathway [3]. More generally genes, which are 









shift  in  the  balance  of  proteins  driving  apoptosis  (e.g.  BIM  and  BAX)  and  factors  that 
block  apoptosis  induction  (e.g.  BCL‐2,  BCL‐XL  and  Mcl‐1)  [7].  Interestingly,  microRNAs 
were shown to regulate pro‐apoptotic factors  like BCL‐2, which  is regulated by the miR‐
15a‐16‐1  cluster and anti‐apoptotic  factors  like BIM, which are  regulated by members of 
the miR‐17‐92 cluster. For instance, aberrant expression of these microRNAs is frequently 
observed in lymphomas [5,8].  





Cancer  cells  acquire  the  ability  to  invade  and  metastasize  into  distant  sites  of  the 
organism  by  following  a  regulatory  program  termed  epithelial‐mesenchymal  transition 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(EMT)  [11].  As  the  EMT  is  a  complex  process,  a  large  variety  of  factors  seem  to  be 
involved.  For  instance,  the  adhesion molecule  E‐cadherin, which  assembles  cells  of  the 
epithelial  layer,  is  frequently  down‐regulated  in  human  carcinomas,  enabling 
intravasation of tumor cells into the blood stream [12]. Metastatic cells, which enter the 
blood stream, have to  leave the blood vessel  into the tissue of a distant organ,  termed 
extravasation, requiring matrix metalloproteinases, which are degrading the extracellular 
matrix  (ECM)  of  the  target  organ.  Finally,  the metastasizing  cells  have  to  colonize  the 
target organ by forming novel macroscopic tumors.  
In  2011,  eleven  years  after  their  remarkable  publication  “The  Hallmarks  of  cancer”, 
Hanahan and Weinberg published an update adding the topics “enabling characteristics” 
and  “emerging hallmarks”  according  to  the gained  knowledge of  the  last  eleven  years 








exhibit  losses  of  telomeric  DNA  leading  to  chromosomal  instability  and  therefore 
resulting  in  amplification,  deletion  or  structural  rearrangements  of  chromosomes  [17]. 
Besides DNA mutations and chromosomal aberrations, epigenetic modifications like DNA 
methylation or histone modifications are contributing to these enabling characteristics.  
Inflammation  is  considered  to  play  an  important  role  in  cancer  progression.  There  is 
increasing  evidence  that  inflammatory  cells,  which  are  present  in  the  near  vicinity  of 
lesions,  supply  the  tumor  with  signaling  molecules  and  thereby  promote  cancer 
progression  [18,19,20].  Accordingly,  the  ability  of  cancer  cells  to  evade  from  immune 
destruction  is  considered  as  an  emerging  hallmark  of  cancer.  Finally,  characteristic 
changes  in  the energy metabolism are  frequently observed  in  cancer  cells.  Cancer  cells 








neoplastic  lesion.  Thus globally,  the  establishment of  a  tumor  is  rather  a  serial  process 
accumulating  several  of  the  aforementioned  properties,  e.g.  by  repeated  exposure  to 
carcinogens with  increasing  age.  Pediatric malignancies  represent  an  exception  to  this 
mechanistic view, as they are characteristic for an early disease progression. 
With  ongoing  research  the  list  of  hallmarks  will  refine  and  increase.  For  instance  the 






neoplasms)  the  distinct  diseases  are  further  characterized  with  respect  to  their  cell 
morphology, immunophenotype, genetic alterations and clinical syndrome.  
In  1832 Thomas Hodgkin  for  the  first  time described abnormalities  in  the  lymph system 
termed  Hodgkin’s  lymphoma  (HL).  The  histopathological  characteristic  are  the 
multinucleated Reed‐Sternberg cells  [22].  In  the  1970 Karl Lennert of Kiel proposed  the 
Kiel  classification  system,  based  on  morphologic  changes  of  malignant  cells  in 
comparison to their normal counterparts [23]. Further research revealed different forms 
of  lymphomas  classified  by  Henry  Rappaport  leading  to  the  “Working  Formulation”  in 
1982  and  introducing  the  term  non‐Hodgkin  lymphoma  (NHL),  which  excludes  the 
classical Hodgkin’s lymphoma. The Working Formulation classified the NHLs into the four 
groups  low  grade,  intermediate  grade,  high  grade  and  miscellaneous  lymphomas 
according  to  size  and  shape  of  neoplastic  cells  [24].  This  classification was  replaced  in 









The  B‐cell  development  starts  in  the  bone  marrow.  In  this  compartment  the  B‐cell 
precursors  arise  from  hematopoietic  stem  cells  and  evolve  by  rearranging  the 
immunoglobulin (Ig) heavy‐ and light‐chain (V)‐region genes for the B‐cell receptor (BCR). 
B‐cells expressing a non‐auto‐reactive BCR are able to differentiate  into mature naïve B‐
cells  and  leave  the bone marrow. B‐cells without BCR expression or with  auto‐reactive 
BCRs  undergo  apoptosis  [26].  Antigen  binding  of  the  BCR  and  the  interaction  with  T‐
helper‐cells activates the naïve B‐cells leading to clonal expansion in the germinal centers 
(GC)  of  lymphoid  follicles  (Figure  1‐1).  In  the  GCs  the  B‐cells  undergo  somatic 
hypermutation  rearranging  the  Ig  variable  (V)‐region  genes  with  the  aim  to  improve 
antigen binding specificity of the BCR [27]. B‐cells expressing BCRs with reduced affinity 
upon  somatic  hyper  mutations  undergo  apoptosis.  The  selection  process  for  B‐cells, 
expressing high affinity BCRs, occurs in the light zone of the GC with close interactions to 
CD4+ T‐cells and follicular dendritic cells (FDC). Finally, a subset of these B‐cells undergo 













proto‐oncogenes,  indicating  that  these  chromosomal  rearrangements most  likely occur 
during  V(D)J  recombination,  somatic  hypermutation  and  class‐switch  recombination 
[32,33,34]. In addition to the rearrangements of BCR‐related genes, genetic modifications 
like  mutations  of  the  tumor  suppressor  gene  TP53  or  ATM  are  implicated  in  the 
pathogenesis of lymphomas as well [35,36,37,38]. Even though B‐cell lymphomas acquire 
genetic  lesions  favoring  their  pathogenesis,  the  vast  majority  of  B‐cell  lymphomas 
additionally benefit of BCR‐promoted cell survival [39]. It is known for several lymphoma 
types  that  their  BCRs  bind  auto‐antigens  supporting  cell  survival  [40,41].  In  addition, 
foreign  antigens,  often  related  to  chronic  infections,  are  also  shown  to  promote 
lymphomagenesis [42]. Infection with the Epstein‐Barr virus (EBV), which is known to be 
involved  in  the  transformation  of  B‐cells,  is  supposed  to  provide  survival‐promoting 
signals through the virus specific gene LMP2A [43,44]. Interestingly, it is shown that EBV 
drives  the  expression  of  a  specific microRNA, miR‐155,  which  plays  a  key  role  in  B‐cell 
immortalization  [45,46,47].  Finally,  there  is  strong evidence  that  the microenvironment 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provides  important  survival  signals  for  malignant  B‐cells.  Several  lymphoma  types  like 










times  ranging  from  a  few  months  to  several  years.  The  median  survival  time  after 
diagnosis is 7.5 years. About 20% of CLL cases show a more aggressive clinical course [50]. 
Patients  with  CLL  have  an  impaired  immunologic  activity  with  a  high  deficiency  of 
immunoglobulins in approximately 50% of cases [51].  Autoimmunity is observed in 25% of 
patients  [52].  For  the  diagnosis  of  CLL  a  persistent  lymphocytosis  greater  than  5,000 







condensed  “soccer‐ball”‐appearing  chromatin  pattern  [50],  (Figure  1‐3).  From  the 
pathological  point  of  view,  lymphocytosis  and  bone  marrow  infiltration  are  the  most 
critical  factors  for  predicting  the  clinical  course  [50].  CLL  cells  present  a  typical 
immunophenotype  with  low  surface  expression  of  immunoglobulins  (Ig)  and  the 
presence of the antigens CD5, CD19, CD20, CD79a, CD22, CD23, CD43 and CD11c [50].  
In order to classify the individual stages of the disease, clinicians use three major staging 
systems:  (i)  described  by  Rai  et  al.  [55],  (ii)  according  to  Binet  et  al.  [56],  or  (iii)  as 
determined  by  the  international  workshop  on  CLL  systems  [57].  Furthermore,  the 
mutational  status  of  IgHV  genes  appears  to  be  of  prognostic  importance.  The median 
survival  time of patients with mutated  IgHV genes  is much higher  than of patients with 
non‐mutated  IgHV  genes  [58].  It  was  believed  that  naïve  B‐cells  with  no  antigen 
experience  were  the  origin  for  CLL  cells  with  unmutated  IgHV  genes  (refer  to  1.2.1), 
whereas  B‐cells  after  antigen  stimulation  in  the  GC  were  suggested  as  the  normal 
counterpart of CLL cells with mutated  IgHV  genes    (refer  to Figure  1‐2). However, gene 
expression profiling of CLL cells showed a similar pattern in cases with either mutated or 
unmutated  IgHV genes, which was most similar to memory B‐cells [59,60]. According to 










Besides  the  pathological  and  immunological  phenotypes,  on  the  cellular  level  CLL  cells 
frequently  exhibit  genomic  aberrations.  These  aberrations  are  identified  using 
fluorescence  in‐situ  hybridization  (FISH)  [61].  A  disease  specific  probe  set  detects 
chromosomal  abnormalities  like  the  deletion  of  regions  on  13q,  11q,  17p,  6q  and 
trisomy 12,  which  are  frequently  occurring  in  CLL  [62].  Additionally,  a  genomic  gain  of 
chromosome 19 and the MYCN oncogene on 2p were  identified using array comparative 
genomic  hybridization  (array CGH)  [63].  Deletions  of  the  chromosomal  arm  17p  were 
shown  to  have  the  worst  prognosis  (Figure  1‐4).  Contrary,  patients  with  a  sole  13q 
deletion exhibit the best prognostic value.  
The  heterozygous  or  homozygous  deletion  of  13q14  is  the  most  frequent  genomic 
aberration in CLL and occurs in other types of lymphoma as well [64]. The chromosomal 
region  13q14  carries  the microRNAs miR‐15a  and miR‐16‐1, which  are  significantly  down 





genotypic  subtypes  [66],  (Figure  1‐4).  The  genes  on  chromosome 12,  which  could  be 
involved in the pathomechanism of CLL are not identified.  
About 20% of CLL patients, predominantly individuals with unmutated IgHV genes, carry a 
deletion  of  the  chromosomal  arm  11q  [62,67].  Interestingly  11q  contains  the  tumor 
suppressor  gene  ATM,  which  is  mutated  in  12%  of  CLL  patients  and  associated  with  a 
poorer outcome of the disease [68].  
In 30% of refractory CLL cases the deletion 17p13 is observed, which is known from other 
cancers [69],  (Figure 1‐4). Translocations  in CLL are typically  involving the chromosomal 
region 14q32, which carries the immunoglobulin genes (refer to 1.2.1). The most common 







Figure  1‐4:  Kaplan‐Meier  analysis  on  overall  survival  of  genetic  subgroups  of  CLL  patients  including 
chromosomal deletions of 17p, 11q, and 13q, trisomy 12 as well as patients with normal karyotype. Source: 
[62] 
With  the  establishment  of  next  generation  sequencing  methods,  previously  unknown 
recurrent mutations  in CLL were  identified.  In a cohort of 255 CLL patients NOTCH1 was 
found  muted  in  12.2%  of  all  cases.  Furthermore,  mutations  in  the  gene  MYD88  were 
identified  in  2.9%  of  CLL  patients  [71].  In  a  second  study  using  exome  sequencing,  the 
NOTCH1 mutation  status was  correlated  to  the overall  survival of CLL patients.  In  these 
studies NOTCH1  mutations were  associated with  31%  of  Richter  syndrome  and  20.8%  of 
chemorefractory CLL cases [72]. Richter syndrome (RS) describes the development of a 




of  the  cell  cycle  and  which  are  relatively  resistant  to  apoptosis  [73].  However, 
proliferating CLL cells can be observed in certain foci termed pseudofollicles in the bone 
marrow  and  lymph  nodes.  In  these  pseudofollicles,  CLL  cells  are  able  to  interact  with 
CD4+ T‐cells and CD14+ myeloid cells, which are supposed to provide  the CLL cells with 
survival  and  proliferation  supportive  signals  [74].  Indeed,  it  was  shown  that  CLL  cells 
could  be  maintained  in  vitro  only  when  accessory  cells  or  their  secreted  factors  are 
present.  [75]. Recently,  the survival promoting role of  inflammatory signaling pathways 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and  cytokines  has  been  demonstrated,  which  provides  further  indication  for  the 
importance  of  the  microenvironment  for  the  survival  of  CLL  cells  [19].  Cell  survival 




of  CLL.  One  of  the  best  characterized  transformation  events  in  CLL  is  the  Richter 
syndrome  (RS)  (described  above).  After  occurrence  of  the  RS  the  disease  is  rapidly 




6%  of  all  Non‐Hodgkin  lymphomas.  MCL  is  an  incurable  disease  with  a  short  median 




some  rare  cases  the CCND1  gene  is not expressed, however  these cases often  show an 
aberrant expression of CCND2 or CCND3. So far the proliferative behavior of the tumor is 
the best criterion for the prognosis of the disease [81]. MCL cells originate from mature B‐
lymphocytes  with  a  typical  gene  expression  pattern  like  in  naïve  B‐cells.  MCL  cells 
colonize  the mantle  zone  of  lymphoid  follicles  (Figure  1‐2)  and  can  be morphologically 
subdivided into a blastoid or a non‐blastoid type [82]. The blastoid variants have a higher 
proliferative  activity  and  a more  aggressive  behavior  than  the  non‐blastoid  cases  [83], 
(Figure  1‐5).  Like  in  CLL,  the  IgHV  genes  appear  to  be  either  in  the  germ  line  status 
(unmutated) or  somatically mutated, which  is observed  in  15‐40% of  cases. However,  in 





Figure  1‐5:  Lymph  node  sections  of MCL  patients with  classical MCL  (left)  and  blastoid MCL  (right).  The 
sections were H & E stained. Source: [85] 
 
Besides  the  defining  translocation  t(11;14)(q13;q32)  there  are  several  other  recurrent 
genetic lesions in MCL. Beà and colleagues identified chromosomal imbalances like gains 
on  chromosome  3q,  7p,  8q  and  18q  or  losses  on  chromosome 13,  6q,  1p  and  11q  by 
performing array CGH [86]. Another study screening 53 tumor samples with matrix‐CGH 
showed  that  chromosomal  deletions  of  8p  and  13q14 were  associated with  an  inferior 
overall  survival  [87].  A more  focused  analysis  of MCL  cases  by  FISH  revealed  common 
gains on 3q26, 8q24, 15q23 and 7p15 and recurrent losses of 13q14, 11q22‐q23, 9p21, 1p22, 
17p13 6q27 and 8p22. Further, deletions of 8p, 9p and 13q14 were associated with a worse 
overall  survival,  supporting  the  findings  of  the  matrix‐CGH  analysis  [88].  The  clinically 
aggressive  variants  generally  show  a  more  complex  karyotype  [86,89].  The  observed 
chromosomal  alterations  suggest  recurrent  defects  of  the DNA damage  pathways.  For 
instance loss of the tumor suppressor gene ATM has been observed in up to 46% of MCL 
patients [38]. In up to 30% of the highly proliferative subtypes the CDKN2A locus encoding 
the  two  important  cell  cycle  regulators  INK4a  and ARF  is  deleted  [90].  The CDK4  gene, 





the  pro‐apoptotic  gene  BIM  is  frequently  deleted  in  MCL  cells  [93].  Cancer  associated 





In  the  1970s  it  was  assumed  that  the  number  of  human  protein‐coding  genes  lies 
somewhere  between  35,000  to  100,000.  By  accomplishing  the  sequencing  of  the 
complete human genome in 2001 the hypothetical number of protein‐coding genes was 
reduced  considerably  [96,97]  and was  estimated  to  approximately  21,000  representing 
only  1.5%  of  the  human  genome  [98].  Historically,  the  highest  proportion  of  the  non‐
protein  coding  sequences  was  considered  as  “junk”  DNA,  which  was  supposed  to  be 
functionally silent and to a great extend derived from viruses. Today one knows that the 




observed.  Thus  innovation  in  non‐coding  regulatory  elements  seems  to  be  the  major 
driving force in the evolution of new species [100].  
With  the  development  of  massive  parallel  sequencing  the  variety  of  regulatory  non‐
coding RNA species is constantly increasing. However, their mechanistic aspects of action 
and  their  regulatory  role are poorly understood. So  far diverse classes  like piwi protein 
interacting  RNAs  (piRNAs),  endoribonuclease‐prepared  siRNAs  (esiRNAs),  enhancer 
associated  RNAs  (eRNAs),  large  intergenic  non‐coding  RNAs  (lincRNAs)  and  activating 
non‐coding RNAs (ncRNA‐a) were identified.  
Piwi‐interacting  RNAs  are  thought  to  silence  transposable  elements  during  germ  line 
development.  Experiments  in  mice  have  shown  that  piRNAs  are  involved  in 
transcriptional  silencing of  target genes  through DNA de novo methylation. PiRNAs are 
extremely abundant in spermatocytes and oocytes. According to their expression pattern 












next  generation  sequencing  Orom  and  colleagues  reported  about  3,000  previously 
unknown non‐coding RNAs. Functional analysis revealed an enhancing effect of ncRNA‐a 
on  the  expression  of  specific  genes.  The  authors  could  show  that  specific  ncRNA‐a 
enhance  the  expression  of  transcripts  encoded  in  the  near  vicinity  of  the  respective 
ncRNA‐a [105].  
In  another  study  Kim  and  colleagues  detected  polymerase II  (Pol II)  recruitment  to 
approximately  3,000 different  activity‐dependent  enhancers  in mouse  cortical  neurons. 
By  performing  high  throughput  sequencing  they  identified  a  novel  class  of  non‐coding 
RNAs with <2kb in length, which they termed eRNAs. The synthesis of eRNAs starts in the 
near  vicinity  of  enhancers  and  furthermore  seems  to  require  a  dynamic  interaction 
between the enhancer and the nearest promoter. The functional role of eRNAs remains 
elusive [106]. 
Large  intergenic  non‐coding  RNAs  (lincRNAs)  represent  another  novel  class  of 
evolutionary  conserved  and  therefore  presumably  functional  RNAs  [107].  The  size  of 
lincRNAs  varies  from  2.3  to  17.2  kilobases.  Guttman  and  colleagues  could  show  that 
specific  lincRNAs are transcriptionally regulated by well‐known transcription factors  like 
TP53  and  NF‐κB  [108].  Several  non‐coding  RNAs  of  this  class  were  functionally 
characterized. For instance Xist plays an important role in X‐chromosome inactivation and 
H19 and Air participate in genomic imprinting [109,110]. LincRNAs like HOTAIR are shown 




One  of  the  most  characterized  non‐coding  RNA  species  is  the  class  of  microRNAs 
(miRNAs),  which  are  organized  in  more  than  100  miRNA  families.  MiRNAs  are  single 
stranded small non‐coding RNAs (ncRNAs) of ~21 nucleotides (nt) in length derived from 
short hairpin precursors  [112]. The  first miRNA  lin‐4 was discovered  in  1993  in C. elegans 
and was  shown  to  regulate  the  lin‐14  gene  [113,114].  Initially,  these  novel  ncRNAs were 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named  small  temporarily  RNAs  (stRNAs).  However,  the  term microRNA  that  defines  a 
certain  class  of  ncRNAs  with  common  properties  like  length,  biogenesis,  expression 
pattern and mode of action has been introduced in 2001 [115,116,117,118]. From this point 
the  number  of  identified  miRNAs  in  plants  and  metazoans  registered  in  the  miRNA 
database “miRBASE” (http://www.mirbase.org) has constantly and rapidly increased.  
1.6.1 MicroRNA biogenesis 
MicroRNA  sequences  are  encoded within  introns  and  exons of  non‐coding  and protein 
coding  genes  [8,119,120].  Roughly  50%  of  all  miRNA  sequences  derive  from  precursor 
molecules  that  are  shared by  several miRNAs  and  are  termed miRNA  clusters  (e.g.  the 
miR‐17‐92  cluster)  [121].  Furthermore,  several  miRNAs  have  paralogues  on  distant 
genomic regions [122].  
As  depicted  in  Figure  1‐6,  there  are  at  least  two  different  mechanisms  for  miRNA 
biogenesis known. In the canonical pathway the primary precursor sequences of miRNAs 
(pri‐miRNAs) are typically polymerase II (Pol II) derived [123,124]. However, a minority of 
pri‐miRNAs  is transcribed by polymerase III  (Pol III)  [125]. The pri‐miRNAs usually consist 
of several kilobases (kb) and contain secondary structures like hairpins. In the nucleus the 
pri‐miRNAs are processed to ~70 nt secondary precursor miRNAs (pre‐miRNAs) [121]. The 
pre‐miRNA  production  is  facilitated  by  the  RNase  III‐type  enzyme  Drosha,  which  is 




portions  (ssRNA)  flanking  the  stem  loop  in  addition.  Finally,  DGCR8  assists  Drosha  to 
cleave  the  bound  stem  loop  approximately  11 nt  distant  from  the  ssRNA  to  dsRNA 
junction  [129,130,131].  In  addition,  it  has  been  shown  that  the  biogenesis  of  several 
miRNAs  requires  accessory  proteins  (e.g.  hnRNP A1  or  KSRP)  bound  to  the 
microprocessor complex during processing of the pri‐miRNA. The protein hnRNP A1 has 
been reported to serve as an auxiliary factor binding to the loop of the pri‐miR‐18a (refer 
to  1.6.5),  thereby  relaxing  the  stem  loop  structure  and  supporting  the  cleavage  by 
Drosha.  Furthermore,  approximately  14%  of  all  pri‐miRNAs  contain  conserved  loops, 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which  could  serve  as  interacting  platforms  for  trans‐acting  factors  like  hnRNP A1 
suggesting a more general regulation of this specific processing step [132,133,134,135].  
The  resulting  pre‐miRNA  is  exported  from  the  nucleus  to  the  cytoplasm  mediated  by 
exportin 5  (EXP5),  a  member  of  the  nuclear  transport  receptor  family  [136,137,138], 
(Figure  1‐6).  The  highly  conserved  RNase III  enzyme  Dicer  further  processes  the  pre‐
miRNA.  The  enzyme  cleaves  the  pre‐miRNA  near  the  terminal  loop,  releasing  a miRNA 
duplex  with  ∼21 nt  in  length  [139,140,141].  In  addition,  Dicer  is  connected  to  the  two 
accessory  proteins  TRBP  and  PACT,  which  are  facilitating  the  loading  of  the  mature 
miRNA into the RNA induced silencing complex (RISC),[142,143]. During the formation of 
an  intermediate  RISC‐loading  complex  (RLC),  one  strand  of  the  miRNA  duplex  is 
incorporated  into  the  RISC  effector  protein  argonaute  (AGO)  whereas  the  passenger 
strand  is  degraded  [144].  The  thermodynamic  stability  of  the  two  ends  of  the  miRNA 
duplex usually determines the strand to be loaded to the complex [145]. In humans, four 
different members of the argonaute protein family (AGO1‐4) are expressed. It is assumed 
that  they  possess  similar  functions,  as  all  four members  of  this  protein  family  seem  to 
bind  the  same miRNA  repertoire  [146,147].  However,  AGO2  is  the  only member  of  this 





termed  pre‐mirtron,  is  enzymatically  debranched  leading  to  the  formation  of  hairpin 
structures. The 5’ or 3’ overhangs of the hairpins are endonucleolytically cleaved by so far 
unknown  enzymes,  producing  the  pre‐miRNA  and  thereby  bypassing  the  Drosha 
dependent processing step. Like in the canonical pathway, the pre‐miRNA is exported to 
the cytoplasm, further processed by Dicer and the mature miRNA  is  loaded to the RISC 
[149,150].  Once  the mature miRNA  is  incorporated  into  the  RISC  (miRISC),  the miRNA 








accounting  for  the  majority  of  differences  in  miRNA  profiles  of  various  cell  lines  and 
tissues [151]. Additionally, they identified miRNAs exclusively expressed in certain tissues, 
raising the question how the expression and biogenesis of mature miRNAs is regulated. 





observed  that  47% of  332  human miRNA genes  tested  are  associated with  CpG  islands, 
suggesting  an  important  role  of  DNA  methylation  in  modifying  the  expression  of  pri‐
miRNA [152].  
The  processing  step  from pri‐  to  pre‐miRNA  is  regulated  as well.  As  recently  reported, 
some accessory proteins  like hnRNP A1, KSHP and SMAD are playing  important  roles  in 
Drosha dependent cleavage of certain pri‐miRNAs [133,134,153]. It has been also observed 
that the main factors for miRNA biogenesis itself (e.g. Drosha, DGCR8 or Dicer) are tightly 
regulated.  Typically,  the  expression  or  activity  of  these  enzymes  is  modified  by  single 
negative feedback loops. Han and colleagues observed that DGCR8 is down regulated by 
its  co‐factor  Drosha,  degrading  the  DGCR8  mRNA.  Conversely,  DGCR8  stabilizes  the 
Drosha protein and  thereby  setting homeostatic  levels of both enzymes  for  a  constant 
miRNA biogenesis [154,155]. The activity of Dicer is controlled through negative feedback 
circuits as well, since several mature miRNAs, e.g.  let‐7 or miR‐130a, have been reported 




The  argonaute  proteins  affect  the  efficiency  of  miRNA  production  as  well.  In  2007, 
Diederichs  and  Haber  reported  that  AGO2  is  able  to  cleave  cytosolic  pre‐miRNAs  to  a 
novel  intermediate  molecule  termed  ac‐pre‐miRNA  (Figure  1‐6)  thereby  enhancing  the 
expression  of  mature miRNAs. Moreover,  they  generally  observed  a  slight  increase  of 
miRNA production after ectopic expression of all human AGO proteins [161].  
Pri‐miRNAs  serve  as  substrates  for  adenine  deaminases  (ADARs)  changing  specific 





Mature miRNAs are actively degraded. Even  though  the  field of miRNA decay  is poorly 
investigated,  recent  studies  in  C.  elegans  and  plants  suggest  an  active  degradation  of 











a  perfect  RNA  double‐helix  pairing  to  the  target  transcript  [112,168].  It  has  been 
experimentally shown that target recognition is extremely sensitive to alterations of the 
seed sequence [169]. Besides the seed pairing, supplementary pairing of the 3’ part of the 
miRNA  is  supportive and plays a minor  role  in  target  recognition. Furthermore, optimal 
location  of  this  additional  pairing  was  observed  at  nucleotides  13‐16  with  at  least  3‐4 
coherent  nucleotide  pairings  [168,170].  The  vast majority  of miRNA  binding  sites  were 
identified  in  the 3’ untranslated  region  (3’UTR) of messenger RNAs.  In  some rare cases 
also  functional miRNA binding  sites were  identified  in  the  5’UTR  and  the open  reading 
frame  (ORF)  of  transcripts  [171].  Grimson  and  colleagues  could  show  that  there  are 
further factors influencing the efficacy of miRNA target recognition. First, miRNA binding 
sites  in the vicinity of high AU content are more effectively  recognized than those with 
low AU content. Second, effective  target  sites  for miRNAs preferentially  reside at both 
ends  of  the  3’UTR  but  not  too  close  to  the  stop  codon  [170].  In  addition,  recent  data 
indicate that proliferating cells specifically express mRNA splice variants with shortened 





RNase H‐like  domain,  which  could  eventually  cleave  the  bound  target  mRNA  [174]. 
Additionally,  GW182  proteins  are  essential  factors  of  the  miRISC.  In  mammals  three 
members (TNRC6A, ‐B and –C) of the GW182 protein family exist. GW182 proteins contain 
glycine  tryptophan  (GW)  repeats  enabling  the  direct  interaction  to  the  AGO  proteins 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[175],  (Figure  1‐6).  GW182  proteins  are  the  actual  effectors  of  the  miRISC  since  they 
mediate the translational repression and destabilization of mRNAs [176,177,178,179,180].  
Once  a  specific  mRNA  is  bound  to  a  miRISC  the  translation  of  the  mRNA  is  inhibited 
and/or  the  mRNA  is  degraded.  To  what  extend  mRNA  targets  are  either  cleaved  or 
translationally  inhibited  is  still  a matter  of  debate  [181].    Various  experiments  revealed 
that repression occurs at three different points of the mRNA translation process. The 7‐
methyl‐guanosine  cap  (m7G)  of  a  mRNA  seems  to  play  a  crucial  role  in  translational 
inhibition [182]. Studies suggest  that miRISCs bound to 3’UTR compete with elongation 
initiation  factor  eIF4E  for  the  m7G  binding  and  therefore  prevent  the  initiation  of 
translation  [183].  MiRISC  binding  interferes  with  the  40S  and  80S  ribosomal  subunit 
recruitment and 80S initiation complex formation [184,185]. The deadenylation of mRNAs 
targeted  by  miRISCs  promotes  translational  repression  as  well  [186].  Furthermore 
experiments suggest mechanisms repressing the translation at the post‐initiation step by 
recruiting proteases degrading the nascent amino acid chain [187,188].  
Deadenylation  and  subsequent  decapping  initiate  the  mRNA  decay.  GW182  proteins 
facilitate  deadenylation,  as  they  recruit  the  deadenylase  complex  CCR4 ‐ NOT1  [178]. 
Furthermore, experiments indicate that the poly(A)‐binding protein (PABP) is required to 
interact with GW182 as well (Figure 1‐6). The PABP connects the poly(A)‐tail of the mRNA 
to  the  miRISC  facilitating  initiation  of  the  deadenylation  reaction  [180,189].  Targeted 
mRNAs  were  observed  to  accumulate  in  specific  cytosolic  structures  like  P‐bodies  or 
stress  granules  (SGs).  It  appears  that  P‐bodies  act  as  sites  for mRNA  decay  since  they 
contain  the  CCR4‐NOT1  deadenylase  complex  and  the  DCP1‐DCP2  decapping  enzyme 
complex  [190,191].  Selbach  and  colleagues  applied  a  novel  technique  termed  pSILAC 
(pulse  stable  isotope  labeling  of  amino  acids  in  cell  culture)  to  determine  proteomic 
changes  upon  ectopic  expression  of  certain  miRNAs.  They  found  that  32  hours  post‐
transfection  the  alterations  on  the  proteome  presumably  caused  by  the  manipulated 
miRNA correlated with a mild reduction of the respective mRNA levels [192]. Hendrickson 
and colleagues performed  immunoprecipitations (IP) with AGO‐specific antibodies upon 
ectopic  miR‐124  expression  in  order  to  co‐IP  and  test  recruitment  of  mRNAs  to  the 
miRISCs. Thereby, they recognized that mRNA degradation accounted for approximately 





miRNA  targets,  miRNAs  were  rarely  observed  to  have  the  opposite  effect.  Recently, 
Eiring  and  colleagues  could  show  that  miR‐328  is  able  to  enhance  the  expression  of 




The  general  discussion  whether  miRNA‐targeted  transcripts  are  rather  destabilized  or 
translationally blocked  remains active and will be  further addressed  in  the  future,  since 
the development of novel technologies to study this question is ongoing. 
1.6.3 MicroRNAs and cancer 
In  2004,  Calin  and  colleagues  performed  expression  profiling  of  miRNAs  in  B‐cells  of 
patients  with  chronic  lymphocytic  leukemia  and  identified  at  least  two  distinct 





CLL  [8].  Interestingly,  miR‐15a  and  miR‐16‐1  were  identified  to  directly  regulate  the 









outcome  [201].  As  body  fluids  are  easily  obtainable  from  cancer  patients  and miRNAs 
exhibit a high stability in these fluids, miRNA expression profiles of patient sera got into 
the  focus  of  research  as well.  For  instance,  high miR‐21  levels  in  the  serum of  patients 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with  DLBCL  were  shown  to  associate  with  relapse‐free  survival  [202].  However,  the 
mechanisms  by  which  the  miRNAs  are  transported  to  the  body  fluids  are  poorly 
characterized.  
1.6.4 MicroRNA‐155 
The  genomic  sequence  encoding  miR‐155  is  located  in  the  third  exon  of  the  B‐cell 
integration cluster (BIC) gene on chromosome 21q21.3. The BIC gene was initially identified 
as a common integration site for the avian leucosis virus (ALV) [203]. Years later Tam and 
colleagues  could  show  that  the  integration of  the  retroviral promoter of ALV activated 
the expression of  the non‐coding BIC gene, determining BIC as a proto‐oncogene [204]. 
BIC  was  shown  to  be  predominantly  expressed  in  lymphatic  organs  like  spleen  and 
thymus  [119].  In  2005,  miR‐155  was  shown  for  the  first  time  to  be  over‐expressed  in 
human B‐cell  lymphomas [205]. Thereafter, an elevated expression of miR‐155 has been 
observed  in DLBCL, Hodgkin  lymphoma (HL) and Epstein‐Barr virus transduced Burkitt’s 
lymphoma  (BL)  [206,207]. MicroRNA‐155  is  20  to  30‐fold  higher  in  expression  in DLBCL 
than  in normal B‐cells [151]. Several transcription factors  like NF‐κB and AP1 or signaling 
molecules  like  TNF‐α  or  INF‐β  were  identified  to  regulate  the  expression  of  miR‐155 
[208,209,210]. Additionally, a regulatory role of miR‐155 on several transcripts like CEBPB, 
SMAD2, BACH1,  ZIC3,  PU.1,  IKBKE,  SHIP1, AID1  and WEE1  has  been  experimentally  shown 







correlation  of  an  enhanced  expression  level  of  the  miR‐17‐92  cluster  and  a  genomic 







miR‐19b‐1  and miR‐92‐1,  respectively.  The miR‐106b‐25  cluster  contains  the miRNAs miR‐
106b, miR‐93 and miR‐25, homologues of miR‐17, miR‐20a and miR‐92‐1, respectively [120]. 
Aberrant  expression  of  the  miR‐17‐92  family  has  been  observed  in  various  tumors  like 
DLBCL,  CLL,  multiple  myeloma  (MM),  hepatocellular  carcinomas,  lung  tumors  and 
medulloblastomas [221,222,223,224,225,226]. It was shown that the proto‐oncogene c‐MYC 





premature  death  [5].  Several  transcripts  regulated  by  miR‐17‐92  were  experimentally 
identified.  Among  these were  pro‐apoptotic  genes  like BIM  and  PTEN  as  well  as  other 
cancer  related  genes  like  CCND1,  HIF‐1a  or  CTGF  [5,231,232,233,234].  According  to  its 
oncogenic properties the miR‐17‐92 cluster got his secondary name “oncomiR‐1”.  
1.7 Aim of the study 
The  microRNA  miR‐155  and  the  miR‐17‐92  cluster  are  aberrantly  expressed  in  various 
cancers  including B‐cell  lymphomas (refer to 1.6.4 and 1.6.5) potentially regulating up to 
several  hundreds  of  transcripts.  It  was  the  aim  of  this  study  to  identify  transcripts 
regulated  by  these  miRNAs  in  order  to  delineate  their  potential  role  in  chronic 
lymphocytic leukemia and mantle cell lymphoma.  
In  a  first  approach,  B‐cell  lines were  screened  for  potential  target  genes  using  current 
standard  techniques  like  expression  arrays,  qRT‐PCR,  luciferase  sensor  assays  and 
Western  blot  analyses  upon  manipulation  of  miR‐155  and  miR‐17‐92  expression  in  cell 
lines.  As  these  results were mild  and  novel  findings  suggested  that miRNAs  in  general 
have limited regulatory effects on single target genes, I established a recently published 
screening  method,  which  is  based  on  immunoprecipitation  of  RNA  induced  silencing 
complexes and subsequent sequencing of co‐precipitated RNA (RIP‐Seq), to identify the 
targetome of miRNAs. Using cells with and without transgenic expression of miR‐155, the 
targetome  of  this  oncogenic  miRNA  should  be  characterized.  A  second  aim  was  the 































































































































































































































































































































































































































































1st / 2nd   Name  Source  Blocking  Dilution  Supplier 
1st  Anti‐α‐Tubulin  Mouse  PBS‐T / 5% milk  1:5000  Sigma‐Aldrich 
1st  Anti‐MAP3K14  Mouse  PBS‐T/ 5% milk  1:2500  Abnova Corporation 
1st  Anti‐RAB5C  Rabbit  PBS‐T / 5% milk  1:1000  Sigma‐Aldrich 
1st  Anti‐TCF4  Rabbit  PBS‐T/ 5% milk  1:1000  Aviva Systems Biology 
1st  Anti‐SOCS1  Rabbit  PBS.T/ 5% milk  1:1000  Abcam 
1st  Anti‐Lamin B  Mouse  PBS‐T/ 5% milk  1:1000  Oncogene res. Prod. 
2nd  Anti‐Mouse IgG  
HRP‐linked  
Horse  PBS‐T / 5% milk  1:5000  Cell Signaling Tec. 
2nd  Anti‐Rabbit IgG  
HRP‐linked 
Goat  PBS‐T / 5% milk  1:5000  Cell Signaling Tec. 









Name  Source  Isotype  Supplier 
Anti‐AGO2  Mouse  IgG1  Abnova 
Anti‐AGO2 (11A9)  RAT  IgG2a  G.Meister (MPI), 
Munich, Germany  
Mouse serum Ig  Mouse  mixed  Santa Cruz  













































































































miRanda  08.2010  http://www.microrna.org/microrna/home.do  [241] 
PICTAR4  03.2007  http://pictar.mdc‐berlin.de/  [242] 
PICTAR5    http://pictar.mdc‐berlin.de/   
RNA22  05.2008  http://cbcsrv.watson.ibm.com/rna22.html  [243] 







































the  suppliers  instructions  the  cell  lines MEC‐1,  Granta‐519  and HEK293T were  cultivated 
with  Dulbecco’s  modified  eagle  medium  (DMEM)  containing  10%  fetal  bovine  serum 
(FBS), 1000 mg/ml D‐glucose and 500 u/ml penicillin/ 500 µg/ml streptomycin. The cell line 
JEKO‐1 was cultivated in RPMI‐1640 containing 20% FBS and 500 u/ml penicillin/ 500 µg/ml 
streptomycin. The cells were  incubated at 37  °C, 95% humidity and 5%  (for RPMI) or  10% 
(for DMEM) CO2. 
2.2.1.2 Generation and maintenance of stable cell lines 
In  order  to  generate  cell  lines,  stably  over‐expressing  miRNAs,  5x106  cells  were 
transfected with 2 µg of  the episomal vector pREP4 containing  the miRNA sequence of 
interest  (Figure  2‐1).  As  negative  control  the  pREP4  vector  backbone was  transfected. 
Transfections were performed using TransIT‐LT1 transfection reagent (Mirus bio LLC) (see 
2.2.2.1)  or  by  Amaxa  nucleofection  (Lonza)  according  to  the  protocol  previously 
established  by  Dr.  Alexandra  Farfsing  [247].  Transfected  cells  were  cultured  under 
Material 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selective  pressure  for  four  weeks  using  a  previously  tested  concentration  of 
hygromycin B.  The  cells were  passaged  every  second  day.  Non‐transfected  cells, which 
were used as positive  control  for  selection,  died  after  approximately  two weeks under 
















and  the  nucleofector  device  from  Lonza.  For  each  transfection  5x106  cells  were 














Plasmid  DNA  isolation  from  up  to  5  ml  bacteria  cultures  was  performed  by  using  the 
Plasmid Miniprep  kit  (Qiagen)  according  to  the manufacturer’s  instructions.  For  larger 
volumes  up  to  300 ml  of  bacteria  cultures  the  Endofree  Plasmid Maxiprep  kit  (Qiagen) 
was used.  
2.2.3.3 RNA isolation 
For  RNA  isolation,  up  to  1x107  cells  were  harvested  and  washed  once  with  PBS  as 
described above. Cell pellets were either stored at ‐80 °C or directly processed using the 
miRNeasy  kit  (Qiagen)  according  to  the  manufacturer’s  instructions,  which  allows  the 
isolation of small non‐coding RNAs in addition to larger RNA species.  
2.2.3.4 Quantification by spectrometry 
The  quantity  and  quality  of  isolated  genomic  or  plasmid  DNA,  and  RNA was  assessed 
using  a  NanoDrop  ND‐1000  instrument  (NanoDrop  Tec.).  Nucleic  acids  are  detected  at 
their maximum absorbance wavelength of  260 nm. Contaminants  like phenol or  amino 
acids containing aromatic residues can be detected at 280 nm and residual ethanol can be 
detected at the 230 nm. Therefore, the optical densities of DNA and RNA preparations at 
these  three  wavelengths  were  acquired  (OD230,  OD260  and  OD280)  and  ratios  were 
calculated. An OD260/OD280 ratio of 1.8 is considered as pure DNA and an OD260/OD280 ratio 








denatured RNA molecules  in a  capillary  filled with a gel matrix according  to  their  sizes. 




The  web  based  tool  “Primer3”  [248]  was  used  at  default  settings 





sites,  the  enzyme  specific  palindromic  sequences  were  added  5’  of  the  gene‐specific 















The  PCR  products  were  cleaned  using  the  Qiaquick  PCR  Purification  kit  (Qiagen) 
according to the manufacturer’s instructions. 
2.2.3.9 Agarose gel electrophoresis 
Agarose  gels  were  prepared  by  adding  1‐3%  (w/v)  agarose  to  TBE‐buffer.  The mix  was 
boiled in a microwave oven and mixed on a stirring device to create a homogeneous gel 
matrix. After casting the gel, DNA samples mixed with sample loading buffer (Fermentas) 
were  loaded  into  the  pockets  of  the  gel.  Typically,  electrophoretic  separation  of  DNA 
molecules was performed for 30 to 60 minutes and 100 V potential. Thereafter,  the gel 








Sanger  sequencing  was  performed  [250]  in  order  to  determine  a  DNA  sequence  of 
interest. This technique is a PCR‐based method that relies on elongation termination after 
incorporation of derivates of all four dideoxynucleotides labeled with four different dyes 
respectively.  The  sequencing  reaction was  performed  according  to  the manufacturer’s 
advices  of  the  PRISM  BigDye  Deoxy  Terminator  Cycle  Sequencing  kit  (Applied 
Biosystems).  Briefly,  the  denaturation  step  lasted  2  minutes  at  96 °C,  followed  by  25 
cycles of 5 seconds at 96 °C, 10 seconds at 55 °C and 4 minutes at 6 °C. After PCR, the DNA 
was precipitated using 100% ethanol and 1/10 volume of 3 M NaAc and washed with 70% 
ethanol.  The  dried  DNA  pellet  was  resolved  in  11  µl  of  deionized  formamide.  DNA 
fragment  separation  and  detection  via  laser‐induced  excitation  of  the  fluorescently 





To  achieve  stable  over‐expression  of  various  miRNAs  in  cell  lines,  the  pre‐miRNA 





was performed by PCR  (see 2.2.3.7) using genomic DNA  isolated  from peripheral blood 
cells of a healthy donor as the template sequence. Gene‐specific primers were designed 
as  described  in  2.2.3.6.  In  order  to  generate  sufficient  insert  DNA  for  the  cloning 
procedure,  35  to  40  PCR  cycles  were  run  on  a  gradient  PCR  machine  with  annealing 







without  insert  DNA  as  well  as  the  orientation  of  the  insert  was  controlled.  The  PCR 
product, which was flanked by restriction sites for these same two enzymes was digested 
accordingly. Routinely, 2 µg of vector DNA or the total amount of the PCR product were 
digested  in  a  50  µl  reaction  mix  over  night  at  37  °C.  The  restriction  products  were 
separated on  a  2%  agarose gel  and  the bands of  the  correct  sizes were  sliced out.  The 
Qiaquick  Gel  Extraction  kit  (Qiagen)  was  used  according  to  the  manufacturer’s 
instructions in order to elute the DNA sequences from the gel slices.  
To  insert  the  DNA  of  interest  into  a  vector  backbone,  the  T4‐DNA  ligase  was  used.  A 
typical reaction mix contained 1 µl of the restricted vector backbone, 2 µl of the restricted 





In  order  to  amplify  the newly  generated  vector,  the  ligation products were  introduced 
into  chemically  competent  TOP‐10  e. coli  bacteria  (Invitrogen).  Briefly,  the  competent 
bacteria were thawed on ice. Roughly 50% of the ligation reaction mix was added to the 
bacteria  and  incubated  for  30 minutes  on  ice.  After  a  brief  heat  shock  at  42  °C  for  30 
seconds,  the  competent  cells were  incubated  for  additional  two minutes  on  ice.  Then, 
700 µl of pre‐warmed LB‐medium was added and the cells were incubated for one hour at 
37 °C and with gentle agitation on an Eppendorf shaker. Finally, the cells were plated on 
LB‐agar  medium  containing  50 µg/ml  ampicillin  and  incubated  for  12  hours  at  37 °C. 
Colonies  growing  on  the  selective medium were  picked  and  transferred  to  5 ml  of  LB‐
amp‐medium. These liquid cultures were incubated over night at 37 °C gently shaking. 
Glycerol‐stocks  containing  700 µl  glycerol  and  300 µl  of  the  bacteria  culture  were 
prepared and stored at ‐80 °C. Plasmid DNA was isolated from the bacteria cultures using 




Quantitative  real‐time  reverse  transcription  PCR  (qRT‐PCR)  was  used  in  order  to 
determine  the  relative  abundance of  a  certain RNA molecule  in  the  sample of  interest. 
Quantification is thereby achieved by monitoring the amount of amplified DNA during the 
PCR after every cycle. For the detection of DNA there are two common methods in use. 






The  primers  for  qRT‐PCR  were  designed  using  the  web‐based  tool  “Universal  Probe 









reaction buffer,  1 µl of DNaseI and filled to 8 µl with H2O. The mix was  incubated for  15 
minutes at 20 °C. Then, 1 µl of 25 mM EDTA, 1 µl of 300 ng/µl random hexamer primer and 
1 µl of 10 mM dNTP mix were added, followed by 10 minutes of incubation at 65 °C and 10 
minutes at 25 °C. Thereafter, 2 µl of 5x  reaction buffer, 2 µl of  100 mM DTT and  1 µl H2O 
were  added  to  the mix  and  incubated  for  2 minutes  at  42 °C.  Finally,  1 µl  SuperScript II 
reverse transcriptase and 0.2 µl of T4p32 protein were added to the reaction mix. The mix 
with  a  final  volume  of  20.2 µl  was  incubated  for  50  minutes  at  42 °C  for  reverse 
transcription and 10 minutes at 94 °C to inactivate the reverse transcriptase. 
2.2.5.3 qRT‐PCR analysis 
A  typical  quantitative  real  time  PCR  reaction  contained  6 µl  SYBR  Green  (Thermo 




°C was  produced  to  test  the  PCR product  specificity.  As  SYBR Green  labels  any  double 
stranded DNA like primer dimers or DNA contaminants, the melting curve is an important 
mean to evaluate the DNA content of the PCR reaction (see 2.2.5). 
To  calculate  the  efficiency  of  the  PCR  for  each  amplicon,  a  dilution  row  of  human 
reference standard cDNA, which was reverse transcribed together with the specific RNA 
samples, was  added on each plate.  The  relative  abundance of  the RNA of  interest was 
normalized to at  least  two of  three house keeping RNAs, DCTN2, PGK1 or GAPDH, which 






Typically,  1x107  cells  per  sample  were  harvested,  washed  once  using  ice‐cold  PBS  and 
lysed  in  100  µl  RIPA‐buffer  (see  2.1.5.4)  containing  1 µl  of  the  endonuclease  Benzonase 
(Merck) to digest genomic DNA. To enhance cell  lysis, the solution was pipetted up and 
down ten times followed by five minutes of incubation at 4 °C on a tumbler machine. Cell 
debris  was  removed  by  centrifugation  at  13,000 rpm  for  10  minutes  at  4 °C.  The 
supernatant containing the proteins was stored at ‐80 °C. 
2.2.6.2 Protein quantification 
The enzymatic biuret  reaction was used to determine the protein concentrations  in  the 
lysates. This assay relies on the reduction of Cu2+ ions to monovalent Cu+ ions in alkaline 
medium. 200 µl of a copper‐(III)‐sulfate and bicinonic acid mix (ratio 1:50) was added to 
10 µl  of  lysate  and  incubated  for  30  minutes  at  37 °C  followed  by  analyzing  the  light 




Dependent  on  the molecular weight  of  analyzed  proteins,  polyacrylamide  gels  ranging 
from  8%  to  12%  polyacrylamide  were  prepared.  To  induce  the  polymerization  of  the 
acrylamide  and  to  stabilize  the  generated  radicals,  ammonium  persulfate  (APS)  and 
N,N,N’,N’‐tetramethylethylendiamine  (TEMED) was  added  to  the  reaction,  respectively. 
Sodiumdodecylsulfate (SDS) was added to the mixture to apply a negative charge to the 
proteins  and  to  keep  them  denatured  during  separation.  The  stacking  gel,  containing 
lower  amounts of  polyacrylamide, was  cast  on  top of  the  separating gel. Alternatively, 
NuPAGE polyacrylamide gradient (4%‐12%) precast gels were used (Invitrogen). 
Protein  samples were  set  to  a  desired  concentration  and  denatured  by  adding  sample 
loading  buffer  (see  2.1.5.4)  and  incubation  at  95 °C  for  10 minutes.  Samples were  then 
loaded  into  the  gel  pockets  and  electrophoresis  was  performed  for  approximately  45 






Proteins  separated  by  SDS‐PAGE  were  transferred  to  polyvinylidene  fluoride  (PVDF) 
membranes  in  a  transfer  tank  (Biorad).  PVDF  membranes  were  activated  in  100% 
methanol  before  protein  transfer  was  carried  out  in  transfer  buffer  (see  2.1.5.3)  for  2 
hours with  250 mA  and  a maximum  of  100 V.  The  transfer  reaction was  cooled  by  ice. 
Membranes were then washed 3 times for 5 minutes in washing buffer (see 2.1.5.4) and 
stored in washing buffer at 4 °C until further processing.  
To  detect  proteins  of  interest  membranes  were  first  blocked  for  one  hour  at  room 
temperature  using  the  indicated  blocking  buffers  (see  2.1.5.4)  followed  by  3  washing 
steps. Antibodies targeting the proteins of interest were diluted as indicated (see 2.1.9.1) 
and incubated on the membrane over night at 4 °C on a rolling machine. After 3 washing 
steps  with  washing  buffer,  the  secondary,  HRP‐conjugated  antibody  (see  2.1.9.1)  was 
applied  for one hour at  room temperature on a  rolling machine. Finally,  the membrane 
was  washed  again  3  times  and  thereafter  incubated  with  ECL  or  ECL+  solution 
(Amersham). Light emission was detected by using a hypersensitive film. 
When using the ECL plex detection system, membranes were blocked with ECL advanced 
blocking  agent  (see  2.1.5.4)  and  incubated  with  two  primary  antibodies  from  two 
different species simultaneously. The incubation with the fluorophore‐coupled secondary 




coomassie  stained  1D gel and  the protein was  reduced with  10 mM DTT  for  1 h at 56 °C 
followed  by  alkylation  of  the  free  sulfhydryl  groups  of  cysteine  residues  with  55 mM 
iodoacetamide  for  30 min  at  room  temperature.  Subsequently,  the  gel  pieces  were 
washed 3 times alternatively with H2O and H2O/acetonitrile (50:50 v/v). After drying with 
neat  acetonitrile,  trypsin  (sequencing  grade,  Promega,  Madison,  USA)  in  40 mM 




in  50%  acetonitrile,  100%  acetonitrile  and  0.1%  TFA.  The  combined  extraction  solutions 
were dried  in a  speed‐vac at 37 °C  for 2 h. Peptides were  redissolved  in 5 µl 0.1% TFA by 
sonication  for  15 min  and were  applied  for  separation on  a  nanoAcquity UPLC  (Waters 
GmbH,  Eschborn, Germany).  Peptides were  trapped on  a  nanoAcquity  C18  column,  180 
µm  x  20  mm,  particle  size  5 µm  (Waters  GmbH,  Eschborn,  Germany).  Separation  was 











Database  search was  performed  using  the NCBInr  database  (release  2009_12_09) with 
the  MASCOT  search  engine  (Matrix  Science,  London,  UK;  version  2.2).  Taxonomy  was 
mammals.  Peptide  mass  tolerance  was  set  to  5  ppm  and  fragment  mass  tolerance  to 
0.6 Da. One missed  tryptic  cleavage  site  in  case  of  incomplete  hydrolysis was  allowed. 












using TaqMan reverse  transcription kit  (Applied Biosystems). The  resulting cDNAs were 
quantified  in a HT7900  real‐time PCR machine using specific primer  sets consisting of a 
miRNA  specific  primer,  a  primer  targeting  the  artificially  elongated  miRNA  part  and  a 
specific probe labeled with fluorophore and quencher. Every PCR amplicon was tested in 
a  dilution  row  of  human  reference  standard  cDNA,  which  was  reverse  transcribed 
simultaneously with the specific RNA samples to calculate the efficiency of the PCR. The 
relative abundance of the miRNA of interest was normalized to two house keeping small 





to  the  manufacturer’s  protocol.  Twenty  nanograms  of  RNA  were  used  for  reverse 




expressed.  The  ct‐values  of  expressed  miRNAs  were  normalized  to  the  median 
expression level of all expressed miRNAs of the respective sample. 
2.2.7.3 Bioinformatic miRNA target prediction 
In  order  to  identify  potential  miRNA  target  genes,  five  different  target  prediction 
algorithms  were  used  (see  2.1.13).  All  prediction  algorithms  have  different  criteria  for 
predicting  mRNA  sequences  as  potential  miRNA  targets.  For  example,  the  RNAhybrid 












was  transfected  together  with  a  TK  renilla  vector  (Promega)  into  HEK293T  cells  (see 
2.2.2.1). Simultaneously,  the cells were transfected with either a miRNA over‐expressing 
vector or the vector backbone as negative control. For these experiments, 4x104 HEK293T 
cells were plated per well  in 48‐well  plates  24 hours before  simultaneous  transfections 
with all three vectors. Cells were harvested 24 hours after transfection, washed once with 
ice‐cold  PBS  and  lysed  by  using  passive  lysis  buffer  (Promega).  Luminescence  signals 
were obtained by sequentially adding 10 µl of  firefly buffer, containing the substrate for 
firefly  luciferase,  and  100 µl  of  renilla  buffer,  containing  a  quencher  for  the  firefly 
luciferase  signal  and  the  substrate  for  the  renilla  luciferase,  to  10 µl  of  cell  lysate.  The 
luminescence  signals  were  quantified  directly  after  the  addition  of  each  of  the  two 
buffers  in  a Mithras  luminescence  reader  (Berthold  technologies).  The  firefly  luciferase 
signal was normalized to the renilla  luciferase signal in each sample. All luciferase assays 
were  performed  in  technical  triplicates  and  at  least  in  four  independent  biological 
replicates. 






complex  (RISC),  immunoprecipitation  (IP)  of  AGO2  protein was  performed.  For  one  IP 
reaction 2x 108 – 4x 108 cells were harvested, washed with ice‐cold PBS and lysed in 400 µl 









machine  followed  by  three  washing  steps  with  1000  µl  NT2  buffer.  Cell  lysates  were 
thawed  on  ice  and  centrifuged  at  13,000 rpm  and  4 °C  for  10  minutes  to  remove  the 
debris. The supernatant was diluted  1:10  in NT2‐buffer and 5 µl RNaseOUT  (Invitrogen), 
2 µl  vanadyl  ribinucleoside  complex  (New  England  Biolabs),  10 µl  of  100 mM  DTT 
(Invitrogen),  10 µl  of  25 mM  EDTA  (Invitrogen)  and  10 µl  protease  inhibitor  cocktail 
(Roche) was added per ml of the mixture. Of this diluted lysate, 100 µl were removed and 
stored on  ice  representing  the  total  lysate  fraction  (TL). The  remaining  lysate was  then 
portioned  to  the  prepared  tubes  containing  sepharose  beads  either  coupled  to  AGO2‐
specific antibodies or to control antibodies. Immunoprecipitation was performed for one 
hour at 4 °C on a  tumbling machine. After centrifugation  the supernatant was  removed 
and stored at ‐80 °C representing the supernatant fraction (SN). The beads were further 
washed five times with 1000 µl of  ice‐cold NT2‐buffer. To elute the bound proteins from 
the  sepharose  beads,  they  were  incubated  in  50 µl  of  1 M  glycine  (pH  2.3)  at  room 
temperature  for  10  minutes.  The  beads  were  spinned  down  and  the  supernatant  was 
neutralized using 50 µl of 1 M Tris‐HCl (pH 8). Thereafter, the proteins were degraded by 
adding 3 µl  of proteinase K  (Qiagen)  to  the neutralized  supernatant and  incubating  the 
mixture for 10 minutes at 55 °C. In order to isolate the co‐precipitated RNA, 350 µl TRIZOL 
LS reagent (Invitrogen) and 100 µl of chloroform was added to the IP‐fraction as well as 
to  the  TL‐fraction.  Phase  separation  was  performed  on  Phaselock  tubes  (3Prime) 
according  to  the manufacturer’s  instructions.  The  aqueous phase was mixed with  100% 


















strand  synthesis  followed  by  second  strand  synthesis.  After  end  repair  and  3’ end 
adenylation  the  sequencing  adaptor  oligo  mix  was  ligated  to  the  unstranded  cDNA 
library.  In  order  to  perform  a  multiplexed  sequencing  run,  six  different  barcoded 
sequencing adaptors were used. The cDNA  library was amplified using  15 cycles of PCR 
according to the manufacturer’s manual (Illumina). The enrichment and size distribution 
of  the  libraries were  tested by Agilent  capillary  gel  electrophoresis  on  a DNA1000  chip 
(refer to 2.2.3.5). The TruSeq libraries were generated from RIP‐Seq samples of HEK293T 
pREP4‐control  and  pREP4miR‐155  cells  as well  as  the  RIP‐Seq material  from MEC‐1  and 
JEKO‐1 cells. 
For sequencing, 6 samples were equimolar pooled per lane. 9 pmol of each sample library 
pool  were  hybridized  per  lane  on  an  Illumina  version 3  single  read  flow  cell.  The 





Sequencing  reads were mapped against  the human  reference genome version  19 using 
the TopHat algorithm version  1.4.0  (2.1.14)  supplying Ensembl gene annotations version 
GRCh37.65 and default settings. RNA levels of 20318 proteincoding genes were calculated 
using  the  HTSeq‐Count  algorithm  version  0.5.3p3  and  default  settings  except  defining 
unstranded sequencing libraries (2.1.14). 








The  resulting  ratios were normalized using  the  function “normalizeQuantiles”  from the 
limma package  version  1.32.0  and  tested  for  differential  enrichment between HEK‐miR‐




Using  flow  cytometry,  cellular  properties  like  granularity  (side  scatter)  or  cell  size 




during  replication.  This  is  used  by  the  EdU  click‐iT  assay  (Invitrogen),  which  was 

















cells, malignant  cells  taken  from  the peripheral blood of  ten CLL and  ten MCL patients 
were  isolated.  Furthermore,  CD19+  B‐lymphocytes  from  the  peripheral  blood  of  three 
healthy donors were used as  reference material. The expression of  the mature miRNAs 
miR‐155,  miR‐17‐3p,  miR‐17‐5p,  miR‐18a,  miR‐19a,  miR‐19b,  miR‐20a  and  miR‐92a‐1  was 





MiR‐92a‐1  was  the  one  exception,  which  was  higher  expressed  in  MCL  patients  in 
comparison to healthy donors and CLL cells. For the miRNAs miR‐17‐5p, miR‐18a, miR‐19a, 
miR‐19b and miR‐20a a lower mean expression was observed in MCL cells, and for miR‐17‐
3p and miR‐92a‐1  a higher mean expression  compared  to CLL  cells. Conversely, miR‐155 
was  up  to  approximately  eight‐fold  higher  expressed  in  CLL  and  MCL  patients  in 

















Identification  of  miRNA  targets  has  been  achieved  by  various  methods  including  the 
usage of bioinformatic target prediction algorithms, qRT‐PCR and Western blot analyses 
to  identify  regulated  genes,  as  well  as  luciferase  sensor  assays  to  evaluate  direct 
interactions of miRNAs with sequences within the 3’UTR of genes. 
In  order  to  identify  potential  target  genes  of  aberrantly  expressed miRNAs  in  CLL  and 
MCL  patients,  mRNA  expression  profiles  of  primary  CLL  and MCL  cells  were  analyzed 
(refer to 3.1). For this purpose transcriptome data of 18 CLL and 6 MCL samples previously 
generated by Dr. Alexandra Farfsing by using Illumina Human Sentrix‐6 BeadChip arrays 
(Illumina  Inc.,  San Diego, USA)  [247] were  analyzed.  Transcripts with  a higher or  lower 
differential  expression  value  than  the  single  standard  deviation  of  the  median  in 






in  comparison  to  healthy  donor  B‐cells,  were  evaluated  for  miR‐19a  target  prediction, 
since this miRNA had “aberrantly” low levels in CLL and MCL (Figure 3‐1). It therefore was 
expected that transcripts, which were repressed by miR‐19a in normal B‐cells, were more 
abundant  in  the absence of  this control. Accordingly, potential  targets of miR‐155 were 
searched within the list of genes, which showed lower expression in CLL and MCL cells. In 




























SGK1  No  Yes  Yes  Yes  Yes 
ETV5  No  Yes  Yes  No  Yes 
RGL1  No  Yes  Yes  Yes  Yes 
TIA2  Yes  Yes  Yes  Yes  Yes 
FOXP1  Yes  No  Yes  Yes  Yes 
CCNT2  Yes  Yes  No  Yes  Yes 
DOCK10  Yes  No  Yes  No  Yes 
E2F8  No  Yes  Yes  No  Yes 
ADNP  Yes  Yes  Yes  Yes  Yes 
ABR  Yes  No  No  Yes  Yes 
NDFIP2  Yes  Yes  Yes  No  Yes 
TNFAIP3  Yes  No  Yes  No  No 




















FBXW7  Yes  Yes  Yes  Yes  Yes 
SGK3  No  Yes  Yes  No  Yes 
CIC  Yes  No  Yes  Yes  Yes 
IRS2  Yes  Yes  Yes  Yes  Yes 
PTGER4  No  Yes  Yes  Yes  Yes 
GIT2  Yes  No  Yes  Yes  Yes 
CDC42  Yes  No  Yes  Yes  Yes 
BCL11A  No  Yes  Yes  Yes  Yes 






























VAV3  Yes  Yes  Yes  No  Yes 
SGK3  Yes  Yes  Yes  No  Yes 
c‐FOS  No  Yes  Yes  No  Yes 
RAB5C  No  Yes  Yes  No  No 
E2F2  Yes  No  Yes  No  Yes 
CSF1R  Yes  Yes  Yes  Yes  No 
Pu.1  Yes  Yes  Yes  No  Yes 
LAT2  Yes  No  Yes  No  No 
PIK3R1  No  Yes  Yes  No  No 
RAB34  Yes  No  Yes  Yes  No 
SIRT1  Yes  Yes  Yes  No  No 
PEBP1  No  Yes  Yes  No  No 
RAP1B  Yes  Yes  Yes  No  No 
Table  3‐3:  Overview  of  potential  miR‐155  target  genes  aberrantly  expressed  in  CLL  or  MCL  and 
computationally predicted as miR‐155 target. 
 
For miR‐19a  twelve  potential  target mRNAs were  found  to  be  higher  expressed  in  CLL 
and/or MCL  cells  and  to  be  predicted  as  a  target  by  at  least  one  prediction  algorithm 
(Table 3‐1). Eight potential miR‐92a‐1 target mRNAs were identified in the list of aberrantly 
expressed transcripts (Table 3‐2). Further, 13 potential target mRNAs were predicted for 






miRNA  expression  in  cells.  To  modulate  miRNA  levels,  commercially  available  miRNA 
precursor (pre‐miR, 2.1.8.2) and miRNA blocking molecules (anti‐miR, 2.1.8.2) for miR‐19a, 
miR‐92a‐1  and miR‐155 were  transiently  transfected  into  the  B‐cell  line MEC‐1  using  the 
nucleofection  system  from  Lonza  (Lonza,  Cologne,  USA)  according  to  the  previously 
established protocol of Dr. Alexandra Farfsing [247] (refer to 2.2.2.2). Total RNA including 
the small RNA fraction was isolated 48 hours after transfection of pre‐miRs and anti‐miRs. 
QRT‐PCR  using  miRNA  specific  primers  was  performed  to  validate  increased  miRNA 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Figure  3‐2:  Quantification  of  miR‐19a  (A),  miR‐92a‐1  (B)  and  miR‐155  (C)  by  qRT‐PCR  after  transient 




Even  though  variations  in  the  levels  of  manipulated  miRNAs  were  detected  in  the 







The  expression  of  potential miRNAs  target  genes was  quantified  by  qRT‐PCR  (refer  to 
2.2.5)  using  RNA  isolated  from  MEC‐1  cells  48  hours  after  transfection.  The  potential 
target genes were measured separately in all biological replicates with pre‐miR and anti‐
miR  treatment.  The  expression  levels were  normalized  to  the mean  value  of  the  three 
house keeping genes DCTN2, PGK1  and GAPDH.  Statistical  significance was calculated by 
performing the student’s t‐test. P‐values lower than 0.05 were considered as significant.  
Twelve, eight and thirteen genes previously  identified for being aberrantly expressed  in 
CLL  or  MCL  and  predicted  as  putative  miRNA  targets  were  tested  for  differential 
expression  after  manipulation  of  miR‐19a,  miR‐92a‐1  and  miR‐155,  respectively. 










for  SGK1  and  DOCK1  (Figure  3‐3).  In  general  the  reduction  or  increase  of  transcript 
abundance  was  on  average  approximately  20%  different  compared  to  the  control 
experiment.  Among  the  twelve  candidate  genes,  there  were  three  genes  significantly 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deregulated  upon  pre‐miR‐19a  or  anti‐miR‐19a  transfection.  Nevertheless,  except  for 
NDFIP2 no other transcript was significantly regulated by pre‐miR and anti‐miR treatment 
in parallel. However, NDFIP2 was equally degraded upon pre‐miR and anti‐miR treatment. 
Unexpectedly, SGK1 was  down  regulated  after  anti‐miR  instead of  pre‐miR  transfection 
and DOCK10 mRNA was increased upon pre‐miRNA instead of anti‐miR transfection. 
 
Figure  3‐4: Quantification of  potential  target mRNAs of miR‐92a‐1,  tested by  SYBRGreen based qRT‐PCR. 
The expression values were normalized to the mean value of the three house keeping genes DCTN2, PGK1 
and  GAPDH.  The  mean  values  of  three  biological  replicates  and  the  statistical  significance  (t‐test)  were 
calculated (*= p< 0.05). The control experiments were scaled to 1 (green line). 
 
Upon  transfection  with  pre‐miR‐92a‐1  or  anti‐miR‐92a‐1,  none  of  the  eight  tested 






















Luciferase  sensor  constructs  were  created  in  order  to  detect  reduced  expression  of 















well  as  the  previously  generated  expression  vectors  pREP4miR‐19a,  pREP4miR‐92a‐1, 
pREP4miR‐155  or  pREP4‐control  (refer  to  3.2.2.5)  into  HEK293T  cells.  The  increase  in 
miRNA levels upon transfection was confirmed by qRT‐PCR (data not shown). The renilla 
luciferase  expression  vector  was  driven  by  a  thymidine  kinase  (TK)  promoter  and  not 




signal  intensities of  the samples with pREP4‐control co‐transfection scaled  to one were 
calculated  (Figure 3‐7  ‐  Figure 3‐9,  red  lines).  Every  luciferase  sensor was  tested  in  four 
biological replicates, which were measured each in triplicates. Statistical significance was 





Figure  3‐7: Results  of  the  luciferase  sensor  assays  of  potential miR‐19a  targets  depicted  as  relative  light 
units (RLU). Firefly  luciferase signals were normalized to renilla  luciferase values and to the empty vector 
control results, which were scaled to 1 (red line). Every experiment was measured in triplicates and in four 
biological  replicates.  The  calculated  mean  values  and  standard  deviations  are  depicted.  Statistical 
significance was calculated by the student’s t‐test (*=p<0.o5). 
 





Figure 3‐8: Results of  the  luciferase sensor assays of potential miR‐92a‐1  targets depicted as  relative  light 
units (RLU). Firefly  luciferase signals were normalized to renilla  luciferase values and to the empty vector 
control results, which were scaled to 1 (red line). Every experiment was measured in triplicates and in four 





Three  luciferase  sensors were  tested  for  responsiveness  to miR‐92a‐1  (Figure  3‐8).  The 
luciferase signals for FBXW7 and IRS2 were enhanced. This effect was statistically robust 
for  FBXW7.  The  luciferase  activity  of  CDC42  was  not  altered  upon  ectopic  miR‐92a‐1 
expression.  
 
Figure  3‐9: Results  of  the  luciferase  sensor  assays  of  potential miR‐155  targets  depicted  as  relative  light 
units (RLU). Firefly  luciferase signals were normalized to renilla  luciferase values and to the empty vector 
control results, which were scaled to 1 (red line). Every experiment was measured in triplicates and in four 
biological  replicates.  The  calculated  mean  values  and  standard  deviations  are  depicted.  Statistical 
significance was calculated by the student’s t‐test (*=p<0.o5). 
 
In  addition,  seven  luciferase  sensors were  tested upon miR‐155 over‐expression  (Figure 
3‐9).  The  luciferase  sensor  for  IKBKE  was  used  as  a  positive  control  since  IKBKE  was 
previously  published  as  a  miR‐155  target  [213].  As  expected,  the  signal  of  IKBKE  was 
significantly reduced by approximately 30% upon miR‐155 over‐expression. The sensor for 
KIF11  was  used  as  a  negative  control,  since  its  3’UTR  contains  no  predicted  miR‐155 
binding  site  (refer  to  2.1.13)  and  the  results  showed  no  significant  changes  of  the 







The  results  from  qRT‐PCR  (refer  to  3.2.2.2)  and  luciferase  assays  (refer  to  3.2.2.3) 
suggested  the  gene  RAB5C  as  a  potential  target  of  miR‐155.  Therefore,  Western  blot 
analyses were performed  in order to confirm these results on protein  level. To this end 
MEC‐1 cells were transfected with pre‐miR‐155 or the corresponding pre‐miR‐control and 
protein was  isolated 24, 48 and 72 hours after  transfection  (Figure 3‐10 A).  In a  second 
approach MEC‐1 cells were transfected with pre‐miR‐155 or anti‐miR‐155 in two biological 
replicates.  Proteins  from  these  cells were  isolated  48h  after  treatment  (Figure  3‐10  B). 
Changes  in RAB5C protein expression were analyzed by Western blot using the ECLplex 
system, scanning the membranes on a Typhoon fluorescence scanner 9000 and analyzing 
band  intensities with  ImageJ. RAB5C and α‐tubulin expression were detected  in parallel 









The  transient  over‐expression  of  miR‐155  in  the  B‐cell  line  MEC‐1  resulted  in  a 
approximately 15% increase of RAB5C protein 24 and 48 hours after transfection and a 10% 
decrease 72 hours after transfection in comparison to the pre‐miR‐control (Figure 3‐10 A) 







To  overcome  uncertainties  of  experiments  using  transient miRNA  over‐expression,  like 
transfection  efficiency,  secondary  effects  of  the  transfection  itself,  and  timing  of  the 
read‐out, cell lines with stable over‐expression of the miRNAs of interest were generated. 
Using stable cell  lines  further creates more flexibility  in performing functional assays to 
characterize phenotypes potentially induced by miRNA manipulation. 
Genomic  sequences  coding  for  miR‐19a,  miR‐92a‐1  or  miR‐155  were  cloned  into  the 
episomal pREP4 vector backbone (refer to 2.2.1.2). By using the RNAfold algorithm (refer 
to  2.1.12)  these  sequences  were  tested  for  potential  RNA  secondary  structures  of  the 
respective  transcripts,  in  order  to  ensure  the  generation  of  hairpins  resembling  the 
structure  of  the  endogenously  expressed  pre‐miRNA,  which  is  necessary  for  proper 
miRNA  biogenesis.  In  order  to  define  the  proper  hygromycin B  concentration  for 
selection,  the  cell  lines  to  be  transfected  were  tested  with  a  range  of  hygromycin B 
concentrations.  Accordingly,  250 µg/ml  and  100 µl/ml  of  hygromycin B were  suitable  to 
strongly  reduce  the  cellular  growth  rates  of MEC‐1  and GRANTA‐519  cells,  respectively. 
The  B‐cell  lines  were  transfected  with  the  vectors  pREP4miR‐19a,  pREP4miR‐92a‐1, 
pREP4miR‐155  and  pREP4‐control  using  the  Lonza  nucleofection  system.  These  cells  as 
well  as  a  mock  transfection  control  were  treated  with  indicated  concentrations  of 
hygromycin B to select for cells containing the pREP4 expression vector. After two weeks 
of  selection  the mock  control  cells were dead.  The  surviving B‐cell  lines  containing  the 
pREP4 vector were cultured under  selective pressure  for  two additional weeks prior  to 
preparing stocks of viable frozen cells. Finally, the cells were tested for miRNA expression 
using  the  miRNA  specific  qRT‐PCR  system  (refer  to  2.2.7.1).  Expression  values  of  the 










The  results  of  the  qRT‐PCR  analyses  showed  that miR‐19a, miR‐92a‐1  and miR‐155 were 
slightly higher expressed in the respective cell  lines compared to the control cell  line. In 
the  stable  MEC‐1  cell  lines  the  expression  of  miR‐19a,  miR‐92a‐1  and  miR‐155  were 



















The  results  of  this  single  Western  blot  showed  that  RAB5C  protein  expression  was 
reduced by approximately 5%  in comparison  to  the control vector cell  line  (Figure 3‐12). 
This observation was consistent with the data upon transient over‐expression of miR‐155 
(Figure  3‐10)  suggesting  a  minor  regulatory  effect  of  miR‐155  on  RAB5C  protein 
expression in MEC‐1 cells. 
3.3 Establishing RIP‐Seq for targetome identification 
As  the above described screening  for miRNA  targets  (refer  to 3.2.2 and 3.2.2.5) did not 
deliver  satisfactory  results,  an  alternative method was  needed.  Therefore,  the  recently 
published  RIP  technique  was  established  and  refined  [252,253].  The  refined  method 
combines the immunoprecipitation of RNA interacting protein (RIP) with subsequent 2nd 














An  efficient  precipitation  of  AGO2  protein  was  the  major  prerequisite  of  the  RIP‐Seq 
method.  Protein  G‐coupled  sepharose  beads  were  coated  with  equal  amounts  of  two 
different monoclonal AGO2‐specific  antibodies.  Isotype  control  antibody‐coupled beads 









2  represent  total  cell  lysates  using  RIPA‐buffer  or  polysome‐lysis  buffer  (PLB).  Lanes  3  and  4  show  the 
supernatant  (SN)  and  IP  fraction  (IP)  after  immunoprecipitation  with  isotype  control  antibody  (IgG1). 
Likewise lanes 5 and 6 represent the SN and IP fractions after AGO2 specific IP. AGO2 protein was detected 




polysome  lysis buffer was used for  immunoprecipitation, as  it  is  less denaturing  leaving 
the  cell  nucleoli  as well  as  protein‐RNA  interactions  intact.  Lanes  3  and  4  (Figure  3‐14) 
represent  the  immunopurification of AGO2 using an unspecific  isotype control antibody 
(IgG1).  AGO2  is  detectable  as  a  band  of  approximately  96kDa  in  the  supernatant  (SN), 
(lane  3). However,  the  signal was  absent  in  the  IP  fraction  (lane  4).  Contrary,  a  strong 









155  showed only  a weak  ectopic  expression of miRNAs  (Figure  3‐11 A & B).  In  order  to 
establish  the RIP‐Seq method,  a  cell  line with  a  strong  over‐expression  of miR‐155 was 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generated. For  this purpose HEK293T cells, which show  low endogenous miR‐155  levels 
were  used.  The  cells  were  transfected  with  the  previously  established  pREP4miR‐155 
(hereafter HEK‐miR‐155) and pREP4empty  (hereafter HEK‐vector) vectors using TransIT‐
LT1 transfection reagent (refer to 3.2.2.5, 2.2.2.1). The transfected cells as well as a mock 
transfection  control  were  treated  with  250 µg/ml  hygromycin B  to  select  for  vector 
containing cells. After two weeks of selection the mock control cells died in culture. The 
surviving pREP4 vector containing cells HEK‐vector and HEK‐miR‐155 were cultured under 









pREP4  vector  backbone  (HEK‐vector)  (Figure  3‐15).  MiR‐155  was  eight‐fold  higher 








Cell  counts of HEK‐vector and HEK‐miR‐155  cultures were assessed  to  identify potential 
differences in the proliferation rates of the cell lines. Briefly, equal amounts of cells were 
seeded  and  counted  after  24,  48  and  72  hours  of  culture.  In  addition,  cell  viability was 
evaluated  using  trypan  blue,  which  stains  dead  cells.  The  assay  was  repeated  at  least 
seven times disseminated over a period of at least three months. Furthermore, different 






automated  cell  counting  device.  Dead  cells  were  excluded  by  trypan  blue  staining  and  the  overall 
proportion  of  viable  cells  was  calculated.  Mean  and  standard  deviations  of  independently  performed 





cells  (Figure 3‐16). After 72 hours of  incubation, a mean  increase of 30% of HEK‐miR‐155 






The  incorporation  rates  of  the  thymidin  analog  EdU  into  DNA  during  replication  were 
monitored  in order  to confirm accelerated proliferation of HEK‐miR‐155  (refer  to Figure 
3‐16). To this end, cells were maintained in confluent cultures for 24 hours to synchronize 
the cells. After reseeding the cells, EdU was added to the medium for 6 hours. The cells 












Comparing  the EdU  incorporation  rates of HEK‐miR‐155 and HEK‐vector cells  revealed a 
difference of 5‐7% after six hours of incubation, indicating enhanced proliferation rates of 







miR‐155  targets  specifically  enriched  in  the  IP  fraction  of  the  HEK‐miR‐155  cell  line 
compared to HEK‐vector. RIP‐Seq was performed as described (refer to 2.2.8 and 2.2.9) 
using a total of 2x108 cells per IP reaction either with AGO2‐specific or IgG1 isotype control 














vector TL and  IP  fractions. However, miR‐155 was approximately  14‐fold enriched  in  the 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PHC2,  a  published miR‐155  target  [192,256],  was  analyzed  as  a  positive  control. GAPDH 
served  as  a  negative  control,  since miRNAs  regulating  this  gene were  supposed  to  be 








MicroRNA  specific  TaqMan  arrays  were  used  to  test  the  miRNA  profile  in  TL  and  IP 
fractions  of  HEK‐miR‐155  and  HEK‐vector  cells.  MicroRNAs  with  an  average  Δct  value 
higher  than  35  were  considered  as  not  expressed  and  were  excluded  from  further 
analyses.  In  total  248  and  193  miRNAs  were  detected  in  HEK‐miR‐155  IP  and  TL, 
respectively. For HEK‐vector cells, 197 miRNAs were detectable in the TL fraction and 249 
in  the  IP  fraction. Figure 3‐20 displays  the  top 30 miRNAs enriched by AGO2  IP of both 
stable cells lines. The Δct values were normalized to the median of all expressed miRNAs 
in the respective sample. Values higher than zero indicate a relatively strong enrichment 




were  similar  in both cell  lines. With  the exception of miR‐155 and miR‐331,  the 30 most 
highly enriched miRNAs were common to HEK‐vector and HEK‐miR‐155. As expected, miR‐
155 was highly enriched in the IP of HEK‐miR‐155, but was underrepresented in the IP of 
the  control  cells  (grey  bars)  again  confirming  the  over‐expression  and  successful 
enrichment of this miRNA in the HEK‐miR‐155 cell  line. As miR‐17, miR‐222, miR‐106a and 
miR‐20a were  present  in  levels  higher  than miR‐155,  the  ectopic  expression  of miR‐155 
was in a physiological range in HEK‐miR‐155 cells.  
 






Comparing  the  miRNA  profiles  of  the  TLs  of  both  cell  lines  revealed  a  differential 
expression  of  57 miRNAs with  a  fold  change  higher  or  lower  than  the  single  standard 
deviation. According to this, 25 miRNAs were higher and 32 miRNAs were lower  in HEK‐







Figure  3‐21:  Comparison  of  the  miRNA  enrichment  profiles  in  the  IP  fractions  of  HEK  pREP4empty  and 
pREP4miR‐155. MiRNAs with enrichment ratios higher than the median are relatively more enriched in HEK‐




matched.  In  case  the miRNA  expression  profile  of  TL  and  enrichment  profile  of  the  IP 
were  equal,  the  ratios  of  all miRNAs  between  TL  and  IP  should  be  relatively  constant. 













hsa‐miR‐222  0.728  hsa‐miR‐155  0.739 
hsa‐miR‐92a  0.732  hsa‐miR‐222  0.746 
hsa‐miR‐221  0.762  hsa‐miR‐92a  0.753 
hsa‐miR‐106a  0.777  hsa‐miR‐501‐3p  0.755 
hsa‐miR‐17  0.784  hsa‐miR‐221  0.774 
hsa‐miR‐320  0.790  hsa‐miR‐320  0.775 
hsa‐miR‐342‐3p  0.792  hsa‐miR‐17  0.787 
hsa‐miR‐197  0.799  hsa‐miR‐342‐3p  0.797 
hsa‐miR‐615‐5p  0.804  hsa‐miR‐20a  0.807 
hsa‐miR‐191  0.809  hsa‐miR‐10a  0.809 
hsa‐miR‐20a  0.815  hsa‐miR‐615‐5p  0.815 
hsa‐let‐7e  0.818  hsa‐miR‐106a  0.828 
hsa‐miR‐10b  0.818  hsa‐miR‐191  0.829 
hsa‐miR‐30b  0.818  hsa‐miR‐125a‐3p  0.832 
hsa‐miR‐501  0.821  hsa‐miR‐125a‐5p  0.835 
hsa‐miR‐30c  0.826  hsa‐miR‐197  0.838 
hsa‐miR‐99b  0.828  hsa‐miR‐425‐5p  0.841 
hsa‐miR‐346  0.830  hsa‐miR‐99b  0.841 
hsa‐miR‐10a  0.830  hsa‐miR‐346  0.843 
hsa‐miR‐125a‐5p  0.830     
hsa‐miR‐193b  0.835     
hsa‐let‐7a  0.836     
hsa‐miR‐542‐5p  0.836     
hsa‐miR‐454  0.837     
hsa‐miR‐186  0.838     
hsa‐miR‐484  0.838     
hsa‐miR‐125a‐3p  0.840     
hsa‐miR‐425‐5p  0.840     





The  reads  were  mapped  against  the  human  reference  genome  version  19  using  the 
TopHat  algorithm.  For  the  IP  and  TL  fractions  35M  and  68M  reads  were  generated, 






To  evaluate  the  effects  of  ectopic miR‐155  expression on  the  global mRNA expression, 
mRNA profiles of TL fractions of HEK‐vector and HEK‐miR‐155 cells were compared. The 
analysis  revealed  that  339  mRNAs  were  down  regulated  and  121  mRNAs  were  up 
regulated in HEK293T cells upon ectopic miR‐155 expression (p<0.05) (Figure 3‐22 A, Table 
S 4 and Table S 5). Notably, among the top 20 over‐expressed genes in HEK‐miR‐155 we 
identified CCND1  and  all  three members of  the  ETS  transcription  factor  subfamily PEA3, 




Table  S  3).  Interestingly,  CCND1  was  also  enriched  in  the  IP  of  HEK‐miR‐155. 
Computational miRNA  target  prediction  for  the CCND1  3’UTR  indicated  the presence of 
several  putative miRNA binding  sites  for miR‐17, miR‐19a, miR‐15, miR‐16‐1, miR‐20a  and 







Figure  3‐22: Volcano  plots matching  TL  (A)  and  IP  (B)  fractions  of  HEK‐vector  and miR‐155.  In  total  463 
mRNAs were aberrantly expressed in TL fractions with 339 significantly down regulated and 121 significantly 
up‐regulated  transcripts  in  HEK‐miR‐155  (black,  p<0.05)  (A).  Matching  the  IP  fraction  of  both  cell  lines 




The  mRNA  levels  detected  in  the  IP  fractions  were  normalized  to  their  respective  TL 




Target  prediction  algorithms  were  used  in  order  to  identify  putative  miR‐155  targets 
within the lists of co‐precipitated mRNAs for both cell lines. For this purpose, five target 
prediction  tools  TargetScan,  MiRANDA,  DianaMicro‐T,  MiRWALK  and  PITA  were  used 
[167,170,237,238,240,241]. Transcripts predicted by at least three of these five algorithms 
with  a  seed  match  of  seven  or  eight  nucleotides  and  a  p‐value  lower  than  0.05  were 
considered  as  putative  miRNA  targets.  These  analyses  revealed  that  miR‐155  was 

























log2‐FC  p‐value    Gene 
Difference in 
log2‐FC  p‐value 
CEBPB*  1,91E+00  4,98E‐05    NFIB*  6,21E‐01  6,18E‐04 
DET1  1,73E+00  2,99E‐05    RGL1  6,21E‐01  1,26E‐03 
PHC2  1,58E+00  9,97E‐06    PAK2  6,20E‐01  3,89E‐04 
TCF4*  1,57E+00  8,97E‐05    BACH1  6,18E‐01  1,44E‐03 
ZFP36*  1,42E+00  1,50E‐04    DUSP14  6,17E‐01  6,88E‐04 
AGTRAP*  1,41E+00  3,99E‐05    CARD10  6,13E‐01  4,09E‐04 
MAP3K10  1,20E+00  1,59E‐04    EID2  6,11E‐01  9,17E‐04 
CSNK1G2  1,11E+00  3,19E‐04    RNF166  5,93E‐01  1,38E‐03 
JARID2*  1,03E+00  2,59E‐04    FBXO9  5,82E‐01  3,59E‐04 
RAPGEF2*  1,01E+00  1,69E‐04    LDLRAP1  5,79E‐01  7,58E‐04 
TRIM32  1,01E+00  1,30E‐04    TRIP13  5,78E‐01  9,07E‐04 
DHX40  9,32E‐01  1,20E‐04    MASTL  5,60E‐01  5,68E‐04 
ZNF320  9,29E‐01  2,39E‐04    CDC42EP4  5,57E‐01  8,27E‐04 
VAMP3  8,93E‐01  2,49E‐04    TMTC2  5,51E‐01  1,63E‐03 
PSKH1  8,89E‐01  6,98E‐05    FOS  5,50E‐01  1,27E‐03 
ATP6V1G1  8,85E‐01  2,09E‐04    BRWD1  5,40E‐01  8,47E‐04 
IER5  8,73E‐01  4,49E‐04    ARFIP1  5,35E‐01  9,27E‐04 
CNNM1  8,40E‐01  1,89E‐04    TAPT1  5,33E‐01  1,72E‐03 
TSHZ3  8,34E‐01  4,78E‐04    TUSC1  5,12E‐01  6,38E‐04 
C3orf18  8,17E‐01  7,48E‐04    RCN2  5,05E‐01  1,96E‐03 
EN2  8,11E‐01  2,19E‐04    RAB34  5,04E‐01  9,37E‐04 
DCK*  7,92E‐01  1,79E‐04    TSPAN14  4,69E‐01  1,18E‐03 
ARRDC2  7,70E‐01  5,28E‐04    C2orf18  4,47E‐01  1,70E‐03 
ZNF652  7,35E‐01  3,09E‐04    CHAF1A  4,36E‐01  1,28E‐03 
BBS7  7,19E‐01  5,98E‐04    EIF5A2  4,25E‐01  1,81E‐03 
EYA2  7,11E‐01  5,18E‐04    ANKFY1  4,22E‐01  1,52E‐03 
ZNF468  6,99E‐01  9,77E‐04    MPP5  4,21E‐01  1,83E‐03 
CTNND1*  6,80E‐01  5,38E‐04    SMAD5  4,17E‐01  1,53E‐03 
ARVCF  6,79E‐01  1,13E‐03    STK38  4,17E‐01  1,50E‐03 
ATP6V1C1  6,73E‐01  3,49E‐04    LRP12  4,10E‐01  1,60E‐03 
GALT  6,70E‐01  1,19E‐03    GNE*  3,90E‐01  1,97E‐03 
TBC1D14  6,70E‐01  1,09E‐03    AHRR  3,90E‐01  1,10E‐03 
DPY19L1  6,46E‐01  5,78E‐04    PDK1  3,65E‐01  1,54E‐03 
MAP3K14  6,32E‐01  9,67E‐04         
Table 3‐5: Predicted miR‐155 target mRNAs, which were significantly (p<0.01, FDR 10%) enriched by AGO2 IP 
of  HEK‐miR‐155  in  comparison  to  the  control  cell  line  HEK‐vector  starting  with  the  strongest  enriched 
mRNA.  Known  targets  (according  to MiRWalk  database)  are marked with  bold  letters.  Genes  negatively 
related to proliferation (according to Ingenuity) are marked with asterisks (*). 
3.3.7.3 MiR‐155 targets related to proliferation 
According  to  cell  counter  and  EdU  incorporation  assays,  HEK‐miR‐155  had  a  significant 
higher  proliferation  rate  in  comparison  to  HEK‐vector  (refer  to  3.3.3).  To  identify 






3.3.7.4 The  miR‐155  mediated  repression  of  CEBPB  causes  increased  CCND1  gene 
expression 
The  miR‐155  target  gene  CEBPB  was  described  to  repress  the  expression  of  CCND1  in 










CEBPB was blocked by  siRNA.  The  knockdown was  tested  after  24h  and 48h of  transfection.  Expression 
values  were  normalized  against  the  mean  of  two  housekeeping  genes  (HK)  DCTN2  and  GAPDH.  CEBPB 
mRNA  levels  were  up  to  40%  reduced  compared  to  scrambled  control  treatments  (blue  columns). 
Simultaneously CCND1 expressions were on average increased by 1.8‐fold (red columns) 
3.3.8 Verification of miR‐155 targets by luciferase sensor assays 
Luciferase  sensors  were  generated  in  order  to  confirm  potential  miR‐155  targets  in 
HEK293T cells identified by RIP‐Seq. Luciferase sensors were cloned for DUSP14, MAP3K14 





for  all  putative  miR‐155  targets  tested  were  decreased  upon  miR‐155  co‐transfection 












the  miR‐155  containing  vector  or  the  corresponding  empty  vector.  48  hours  post‐
transfection the cells were harvested and proteins were isolated from three cellular sub 
fractions  (cytoplasm,  membranes/ organelles  and  nucleus).  The  protein  fractions  were 
tested  for  the  putative  miR‐155  targets  TCF4  and  MAP3K14.  Furthermore,  SOCS1  was 





Figure  3‐26:  Western  blot  analysis  of  putative  miR‐155  targets  in  HEK293T  identified  by  RIP‐Seq.  The 
proteins were separately isolated from cellular sub‐fractions. 
 
According  to  the  results  of  the  Western  blots  MAP3K14  protein  levels  were  clearly 




MCL with potential pathomechanistic  relevance.  To  this  end RIP‐Seq  studies of  the  cell 





three  biological  replicates  of  JEKO‐1  was  not  successful  and  thus  was  not  further 
processed. The 50bp reads were mapped against the human reference genome version 
19  using  the  TopHat  algorithm.  RNA  expression  profiles  of  the  total  lysates  or  the 
enriched  mRNAs  in  the  IP  fractions  were  calculated  using  the  HTSeq‐Count  algorithm 

















Log2‐fold  changes  of  AGO2  IP  versus  control  IP were  calculated  and  transcripts with  a 
log2‐fold change of at  least 0.6 and a p‐value of p<0.05 were considered as significantly 
over‐represented  in  the  AGO2  IP.  In  total,  1,096  and  1,379  mRNAs  were  significantly 
enriched  in  the  AGO2  IP  of  MEC‐1  and  JEKO‐1,  respectively.  Moreover,  there  was  an 









































Furthermore,  putative  miRNA  targets  in  MEC‐1  and  JEKO‐1  identified  by  RIP‐Seq  were 





3.5 Integration  of  targetome  and  miRNA  data  of  MEC‐1  and 
  JEKO‐1 





















miR‐106a    0.492  510  miR‐21    0.660  167 
miR‐155    0.498  144  let‐7e    0.667  237 
miR‐17    0.508  211  miR‐142‐3p    0.668  211 
miR‐20a    0.524  39  miR‐106b    0.673  424 
miR‐92a‐1    0.532  242  miR‐16    0.675  323 
miR‐19b    0.534  304  miR‐484    0.681  289 
miR‐146a    0.536  209  miR‐365    0.682  198 
miR‐191    0.585  61  miR‐15b    0.683  317 
miR‐222    0.615  192  miR‐25    0.692  290 
miR‐342    0.621  273  miR‐24    0.694  277 
miR‐30b    0.622  282  miR‐18a    0.702  132 
miR‐193b    0.624  226  miR‐320    0.715  364 
miR‐30c    0.624  282  let‐7d    0.721  263 
miR‐20b    0.650  499  miR‐29a    0.732  263 
miR‐150    0.652  356  miR‐223    0.736  192 
Table  3‐8:  Summary  of  the  top  30  miRNAs  enriched  in  the  IP  fraction  of  MEC‐1.  The  relative  Δct‐value 
indicates  the abundance of  the  respective miRNA  relative  to  the median of  all  expressed miRNAs of  the 





were  predicted  to  bind  to  at  least  one  of  the  top  30  enriched  miRNAs.  On  average 























miR‐106a   0.433  592  miR‐106b   0.652  499 
miR‐20a   0.440  44  miR‐25   0.653  337 
miR‐17   0.440  259  let‐7e   0.656  256 
miR‐92a‐1   0.441  289  miR‐342‐3p   0.666  307 
miR‐19b   0.458  349  miR‐15b   0.674  393 
miR‐20b   0.598  578  miR‐142‐3p   0.691  177 
miR‐484   0.605  362  miR‐26a   0.699  313 
miR‐146a   0.609  241  miR‐24   0.712  322 
miR‐193b   0.611  278  miR‐19a   0.713  328 
miR‐155   0.611  118  miR‐345   0.714  236 
miR‐30c   0.615  285  miR‐339‐5p   0.717  282 
miR‐18a   0.623  152  let‐7a   0.718  241 
miR‐30b   0.625  285  miR‐365   0.719  178 
miR‐191   0.634  63  let‐7d   0.721  276 
miR‐16   0.642  395  let‐7b   0.728  242 
Table  3‐9:  Summary  of  the  top  30  miRNAs  enriched  in  the  IP  fraction  of  JEKO‐1.  The  relative  Δct‐value 
indicates  the abundance of  the  respective miRNA  relative  to  the median of  all  expressed miRNAs of  the 




Out  of  the  1,379 mRNAs  identified  by  RIP‐Seq  of  JEKO‐1  cells  (refer  to  3.4),  1,134 were 
predicted to bind to at least one of the top 30 expressed miRNAs. On average more than 
6  miRNAs  were  predicted  to  be  associated  per  enriched  mRNA.  The  TSC1 mRNA  was 
present in the IP fractions of both cell lines and was predicted to be a target of 25 of the 
top  30  expressed  miRNAs.  As  previously  mentioned,  BTG2 was  the  most  significantly 
enriched mRNA in both cell lines. The integration of miRNA and mRNA data revealed that 
among the top 30 miRNAs of MEC‐1 and JEKO‐1, 18 were predicted to bind to BTG2 mRNA. 
These  findings  suggest  a  cooperative  mode  of  action  of  miRNAs,  where  mRNAs  are 
simultaneously regulated by numerous miRNAs. 
3.6 Recurrent disproportional association of miRNAs with AGO2 
MicroRNA  profiles  of  IP  and  TL  fractions  of  both  cell  lines were  compared  pairwise  in 




miRNA  levels  in  the  IP  versus  the  TL  fractions  of  each  sample  were  calculated  and  a 
median value of these ratios was determined. MicroRNAs with ratios higher or lower than 
the single standard deviation of  the median value were considered as disproportionally 
enriched  or  depleted  in  the  IP  fraction.  In  general,  an  enrichment  of miRNAs  in  the  IP 
fractions  of MEC‐1  and  JEKO‐1  was  observed.  Interestingly,  the  IP  of  JEKO‐1  showed  a 











The majority  of  disproportionally  enriched miRNAs  in  the  IP  fractions were  among  the 
most  strongly  expressed  miRNAs,  but  there  were  also  miRNAs  with  a  below  average 






Figure  3‐29: Summary of  recurrent  disproportionally  detected miRNAs  in  the  IP  and TL  fractions of HEK‐















However,  all  of  these methods have  their  specific  caveats  including  labor  intensity  and 
detection sensitivity. 
4.1.1 Manipulation of intracellular miRNA levels  
The  artificial  modification  of  miRNA  levels  is  the  pre‐requisite  for  the  observation  of 
miRNA  specific  effects  on  gene  expression.  Specifically  designed  and  commercially 
available miRNA precursor (pre‐miRNAs) or miRNA blocking molecules (anti‐miRNAs) are 
commonly  used.  Alternatively,  expression  constructs  for  over‐expression  or  so  called 
miRNA‐sponges  for  their  inhibition  are options  for miRNA manipulation  [260].  In  2008, 
Sven  Diederichs  and  colleagues  could  show  that  co‐expression  of  AGO2  during  siRNA‐
mediated  silencing  of  genes  enhanced  the  knockdown  effect  [261].  According  to  this, 
AGO  proteins  as  the  central  part  of  the  RISC might  be  one  of  the  limiting  factors  for 
miRNA mediated gene regulation, as miRNAs and siRNAs are using the same machinery. 
Thus,  the  artificial  alteration  of  miRNA  expression,  especially  the  over‐expression  by 
miRNA  mimics  or  expression  vectors,  might  alter  the  residence  of  endogenously 
expressed  miRNA  in  the  effector  complexes,  which  probably  leads  to  undesired 
secondary effects. Furthermore, the transfection of miRNA mimics or miRNA expression 











minor  differences  within  the  group  of  the  top  30  enriched  miRNAs.  28  of  the  top  30 
enriched miRNAs in HEK‐miR‐155 were shared by HEK‐vector. As expected, miR‐155 itself 
was  one  of  the  two  differentially  enriched  miRNAs.  Furthermore,  four  endogenously 
expressed miRNAs  still  showed a higher presence  in AGO2 precipitates  suggesting  that 
the  stable,  artificial  expression  of miR‐155  in HEK293T  cells was  at  physiologic  relevant 




Expression  arrays  are  commonly  used  to  screen  for  miRNA  target  genes  upon 
manipulation of miRNA levels. Potential target candidates are then usually confirmed by 
qRT‐PCR. However, this approach is based on the assumption that all miRNA targets are 
degraded  upon  miRNA  target  binding  of  the  RISC.  Recent  publications  indicate,  that 
indeed  the  majority  of  miRNAs  targets  are  subsequently  degraded  [192,194,262]. 
However, there are exceptions. Willimott and Wagner for instance could show that miR‐
155  regulates  the  protein  expression  of  BCL2  which  contributes  to  an  enhanced  cell 
proliferation  without  affecting  levels  of  the  corresponding  mRNA  and  thus  cannot  be 
detected by transcriptome analysis [254]. In general, miRNAs are thought to act as fine‐
tuning  molecules  causing  mild  changes  on  target  mRNA  expression  [263].  It  is  thus 
feasible,  that  most  target  genes  may  not  be  identified  by  expression  arrays,  as  the 






and  knockdown  simultaneously.  This  might  be  due  in  part  to  high  variations  in  the 
transfection efficiencies of the B‐cell line used for these experiments. However, analyzing 
these  genes  in  the  B‐cell  lines  stably  over‐expressing  the  miRNAs  of  interest  likewise 
resulted in mild effects without significance. 
A second caveat of mRNA expression profiling for miRNA target identification is the lack 
of  distinction  between  direct  miRNA  targets  and  secondary  effects  (later  discussed  in 
4.1.4).  
4.1.3 Identifying miRNA targets via protein analysis 
Luciferase  sensor  assays  are  state  of  the  art  experiments  to  confirm  miRNA‐induced 
effects  on  protein  level.  These  assays  are  labor  intensive  and  not  feasible  for  broad 
miRNA  target  screens,  since  they  require  the generation of  individual  luciferase  sensor 
constructs  for  every  putative  miRNA  target  of  interest.  Additionally,  luciferase  signals 
showed  strong  fluctuations  within  replicates  and  therefore  required many  repetitions. 
Finally, putative miRNA binding sites need to be mutated to proof the functionality of this 
binding site.  
In  the  present  study  luciferase  sensors  were  generated  for  19  genes  to  analyze  their 
potential regulation by miR‐19a, miR‐92a or miR‐155. Of these, eight showed a statistically 
robust  reduction  of  the  firefly  luciferase  signal  after  enforced  expression  of  the 
respective miRNA. According to these analyses RAB5C and RAB34 were identified as novel 
potential miR‐155  targets.  Control  experiments with mutated miR‐155  binding  sites  are 
planed.  Subsequent  Western  blot  analyses  in  B‐cell  lines  with  transient  and  stable 












PAR‐CLIP  (photo‐activatable‐ribonucleoside‐enhanced  crosslinking  and 
immunoprecipitation),  HITS‐CLIP  (High‐throughput  sequencing  of  RNA  isolated  by 
crosslinking immunoprecipitation), RIP‐Chip and RIP‐Seq are recently described strategies 
to identify RNA‐protein interactions. In contrast to the RIP technique, HITS‐CLIP and PAR‐




In  the  present  study,  the  RIP‐Seq  method  was  established  according  to  the  protocol 
published  by  Keene  and  colleagues  [269].  AGO2  protein  was  successfully 
immunoprecipitated  and  co‐precipitated  miRNAs  and  their  target  mRNAs  were 
subsequently analyzed by 2nd generation sequencing.  In order  to proof  the concept of 
this  technique,  HEK293T  cells  showing  a  poor  endogenous  miR‐155  expression  were 
stably transfected with either miR‐155 (HEK‐miR‐155) or the corresponding empty vector 
(HEK‐vector) to identify the miR‐155 targetome. Comparing the mRNA profiles of the TL 
fractions  revealed  that  the  over‐expression  of  miR‐155  resulted  in  a  deregulated 
expression of hundreds of genes. It is likely that several down‐regulated mRNAs in the TL 
of HEK‐miR‐155 are predicted as miR‐155 targets but might not be direct target genes of 
miR‐155  (false  positives).  On  the  other  hand  genes  that  were  increased  upon  over‐
expression of miR‐155 might be co‐precipitated by AGO2 IP due to binding of endogenous 
miRNAs as a secondary event. These could also be predicted as miR‐155 targets and thus 
might be  false positives as well. For  instance, CCND1 was highly enriched by AGO2  IP of 
HEK‐miR‐155.  In  silico  analysis  of  the  CCND1  3’UTR  showed  the  presence  of  several 
putative miRNA‐binding sites,  including one  for miR‐155 suggesting  that CCND1  is a miR‐
155  target  in  these  cells.  Contradictory  to  that,  the  CCND1  expression  was  also  18‐fold 
increased  in  the  TL  fraction  of  HEK‐miR‐155.  Thus,  upon  enforced  miR‐155  expression, 
CCND1 might be stabilized by miR‐155 explaining the enhanced presence and enrichment 
in  TL  and  IP  fractions  of  HEK‐miR‐155.  However,  stabilizing  properties  of  miRNAs  on 
target genes is a rarely described effect. Alternatively, the increased expression of CCND1 
could  be  an  indirect  event  after miR‐155  over‐expression  and  the  enrichment  of CCND1 
mRNA  in  the  IP  of  HEK‐miR‐155  cells  was  due  to  binding  to  endogenously  expressed 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miRNAs  like  miR‐16,  miR‐106a  and  miR‐92a.  Indeed,  CCND1  was  previously  shown 
regulated  by  miRNAs  like  miR‐15/16  and  members  of  the  miR‐17‐92  cluster,  which  are 
highly  expressed  in  HEK293T  cells  [257,258].  In  addition,  CCND1  was  described  being 
negatively  regulated  by  CEBPB,  a  well‐established  miR‐155  target  [211,259]  that  was 
identified by RIP‐Seq  in this work as well. Knockdown experiments using CEBPB‐specific 
siRNAs revealed  increased CCND1  levels,  supporting this hypothesis. A  recent study that 




lines  were  normalized  to  their  respective  TL  fractions,  assuming  that  primary  miRNA 
targets  are  enriched  in  the  IP  and/or  degraded  in  the  TL  fraction.  Accordingly  100 
transcripts,  including  67  known  and  putative  miR‐155  targets,  were  identified  (p<0.01, 
FDR 10%). Notably, of the 67 potential miR‐155 targets only 9 (e.g. BACH1 and JARID2) were 
identified  by  a  significant  (p<0.05)  decay  of  mRNA  in  the  TL  fraction  and  only  minor 
changes in the IP fractions. In addition, 20 potential miR‐155 targets were identified by a 
strong  enrichment  in  the  IP  of  HEK239T  pREP4miR‐155  without  significant  (p<0.05) 
changes  in  the  TL  fraction  (e.g.  PHC2  and DUSP14),  suggesting  that  these  were  rather 
exclusively  regulated  by  translational  repression. Notably,  one  target  gene, ZFP36, was 
simultaneously identified by significant enrichment in IP and decay in the TL fractions of 
HEK miR‐155.  The  vast majority  of  putative miR‐155  targets  showed  however  a modest 
enrichment  in  the  IP  fraction  and  a  simultaneous  and  modest  degradation  in  the 













it  has  caveats  as well.  In  comparison  to  the  PAR‐CLIP method,  RIP‐Seq  cannot  directly 
specify  miRNA‐mRNA  interactions.  Therefore,  miRNA  target  prediction  algorithms  are 




least  three  out  of  five  tested  prediction  tools.  This  implicates,  that  some  of  the  real 
miRNA  targets  were  probably  not  detected  from  the  analysis.  Furthermore,  the 




Taken  together  these  data  indicate  that  the  over‐expression  of  miR‐155  alters  the 
expression  of  hundreds  of  genes.  Many  of  these  were  not  enriched  by  RIP  and  are 






Phenotypic  characterization  of  the  established  HEK‐miR‐155  cell  line  revealed  an 
enhanced  proliferation,  as  identified  by  two  independent  assay  types.  Interestingly,  it 
was previously  reported  that miR‐155 enhances proliferation of other  cell  types  as well 
[254,255].  The presented RIP‐Seq experiments  identified  several  novel  and  known miR‐
155  targets  (e.g.  ZFP36,  CEBPB  and  CTNND1)  with  a  regulatory  function  in  cellular 
proliferation. One of the most differentially enriched transcripts is the zinc finger protein 
ZFP36.  This  protein  is  a RNA destabilizing  enzyme,  recognizing AU‐rich  elements  (ARE) 
within  transcripts  [272].  It  is  frequently  decreased  in  human  cancers  with  a  negative 





related  regulator  of  cell  cycle  [274,275]. A miR‐155 mediated down  regulation of  ZFP36 
might  therefore  contribute  to  the  observed  increase  of  CCND1.  Further,  as  indicated  in 
4.1.4, CEBPB negatively regulates CCND1 expression as well. It is feasible, that the increase 
of CCND1,  caused  by miR‐155 mediated  reduction  of CCND1  regulating  factors,  is  in  part 
responsible for the enhanced proliferation of HEK‐miR‐155. However, the effect of ZFP36 
on CCND1 in HEK293T remains to be tested. Further, the preformed RIP‐Seq experiments 
suggested a  subsequent  regulation of CCND1  by endogenous miRNAs.  It  thus has  to be 
addressed,  if  the  increase  of  CCND1  mRNA  is  reflected  by  an  equal  increase  of  cellular 
CCND1 protein. 
Another  highly  enriched  potential  novel  miR‐155  target  is  CTNND1,  a  protein,  which  is 
directly  regulated  by  trans‐membrane  proteins  like  E‐cadherin  [276].  In  a  study  using 
human colon carcinoma cells, it was shown that CTNND1 overexpression was associated 
with a reduced cell cycle progression [277].  
According  to  the  Ingenuity  database  up  to  10  known and novel miR‐155  targets, which 
were  identified  by  the  present  RIP‐Seq  experiments,  are  negatively  associated  with 
proliferation. It has to be addressed in future experiments whether the regulation of one 
of these genes or a combination of several of them (later discussed in 4.3) is responsible 
for  the  enhanced  proliferation  of  HEK‐miR‐155  cells.  In  addition,  it  has  to  by  clarified 
whether the observed phenotype is a long‐term effect of miR‐155 over‐expression, since 




the  miR‐17‐92  cluster  in  order  to  delineate  their  potential  role  in  chronic  lymphocytic 
leukemia  and mantle  cell  lymphoma.  Established mouse models with  aberrant miR‐155 
and  miR‐17‐92  expression  already  pointed  to  a  contribution  of  these  miRNAs  to  the 
development of leukemic B‐cells [216,218,219,230]. In the present study, RIP‐Seq was used 
to identify genes regulated by miRNAs in the B cell lines MEC‐1 and JEKO‐1, including miR‐
155  and  miR‐17‐92.  Thereby,  1,096  AGO2‐associated  mRNAs  were  identified  in  MEC‐1, 
including  144  potential  miR‐155  targets  and  242  potential  miR‐92a‐1  targets,  as  well  as 
Discussion  
 100
1,379 potential miRNA target genes,  including  118 and 289 potential  targets  for miR‐155 
and miR‐92a,  respectively  in  JEKO‐1  cells.  Of  these,  688  potential  miRNA  targets  were 
common to both cell  lines. Comparing the RIP‐Seq data with published PAR‐CLIP results 
using lymphoblastoid B‐cells [278] revealed an overlap of 609 and 607 miRNA targets to 
MEC‐1  and  JEKO‐1  data,  respectively.  In  general,  it  is  assumed  that  30%  of  the  human 
genes are regulated by miRNAs [278]. PAR‐CLIP experiments identified several thousand 
genes  associated  to  one  of  the  four  AGO  proteins  [147].  For  instance,  the  above 
mentioned  PAR‐CLIP  study  with  lymphoblastoid  B‐cells  identified  approximately  3,500 
miRNA target genes [278]. However, the obtained RIP‐Seq data using JEKO‐1 and MEC‐1 
identified roughly 1,000 miRNA targets per cell line. Since RIP‐Seq does not include cross‐
linking  of  the  AGO protein with  the  attached miRNA  and mRNA,  the  sensitivity  of  this 
method might be lower, resulting in the identification of mainly highly regulated miRNA 
targets  genes.  PAR‐CLIP  that  is  based  on  cross‐linking  of  protein  and RNA, more  likely 
also identifies less stable and more transient miRNA targets. 











upon  genotoxic  stress.  Further,  the  authors  suggested,  that  BTG2  is  a  novel  tumor 
suppressor  gene  with  anti‐proliferative  properties  [281].  Years  later,  BTG2  was  shown 
involved  in  gene‐specific  histone H4  methylation  and  acetylation  and  thereby 
contributing to retinoic acid mediated differentiation of myeloid  leukemia cells [282].  In 
the present work up to 18 of the 30 most highly expressed miRNAs in both leukemic B‐cell 





Several  potential  miRNA  targets  identified  by  RIP‐Seq  in  MEC‐1  and  JEKO‐1  were 
previously  tested  as  miR‐155,  miR‐19a  or  miR‐92a‐1  targets  using  qRT‐PCR,  luciferase 
sensor assays and Western blot analyses. Of these transcripts, 8 and 11 were identified by 
RIP‐Seq in JEKO‐1 and MEC‐1, respectively. Especially FBXW7, a known tumor suppressor 
gene  [283] and RAB5C were down  regulated  in MCL and CLL patients and  identified by 
RIP‐Seq in leukemic B‐cell lines. FBXW7 was tested as potential miR‐92a‐1 target in MCL by 
qRT‐PCR and  luciferase  sensor assays  (refer  to 3.2.2.2  and 3.2.2.3). As detected by qRT‐
PCR, transfection of pre‐miR‐92a‐1 and anti‐miR‐92a‐1  in MEC‐1 cells slightly decreased or 
increased FBXW7, respectively. However, these findings were just a trend, which might be 
due  to  the  already  discussed  fine‐tuning  properties  of  miRNAs.  Surprisingly,  luciferase 
sensor assays  indicated a significant  increase  in FBXW7 expression upon enhanced miR‐
92a‐1  levels. FBXW7 was further  identified as a target of 9 and 12 of the top 30 enriched 
miRNAs,  including  miR‐92a‐1,  in  JEKO‐1  and  MEC‐1,  respectively.  Together  these  data 
suggest that FBXW7 is a target of miR‐92a‐1.  
Strikingly,  qRT‐PCR,  luciferase  sensor  assays,  Western  blot  analyses  and  RIP‐Seq 
identified RAB5C as a miR‐155 target in JEKO‐1 and MEC‐1 cells, suggesting a potential role 
of  this  gene  in  MCL  and  CLL.  Of  note,  RAB5C  protein  levels  were  just  rarely  affected 
supporting  the general  notion  that miRNAs are  fine‐tuners of  target genes. RAB5C  is  a 
small  GTPase  of  the  RAS  protein  superfamily  that  shares  86%  identity  to  RAB5A  and 
RAB5B  [284].  It  was  shown  that  RAB5C  is  a  regulatory  component  for  receptor 
endocytosis  and  endosome  dynamics  [285].  During  zebrafish  gastrulation,  RAB5C  was 
shown  to  be  involved  in WNT11  and  E‐cadherin  mediated  tissue morphogenesis  [286]. 
Interestingly, RAB34 another GTPase down regulated in CLL patients, which is predicted 
as  a miR‐155  target  and which was  confirmed  by  luciferase  sensor  assays  and  RIP‐Seq 











in  leukemic B‐cells  [211,216]. However, CEBPB was  just  identified  in  the  IP of JEKO‐1, but 










Interestingly,  several  components  of  the  miRNA  biogenesis  pathway  were  also  AGO2‐
associated  in  JEKO‐1  and MEC‐1.  DICER1,  a  central  factor  facilitating miRNA maturation 
(refer to 1.6.1) was significantly enriched in the AGO2 IPs of both cell lines. Furthermore, 
the mRNA  of AGO2  itself  was  highly  and  significantly  enriched  in  the  IP  of  JEKO‐1  and 
MEC‐1, indicating that the miRNA biogenesis and activity is regulated in negative feedback 
loops as previously suggested by other groups [155,156,157].  
To  confirm  the  relevance  of  known  and  newly  identified  miRNA  targets  in  B  cell 









4.3 MicroRNAs  with  limited  regulatory  abilities  for  single 
transcripts and severe phenotypic effects: a paradox? 
The  manipulation  of  miRNA  levels  in  animal  models  has  frequently  resulted  in  severe 
phenotypes.  For  instance,  mice  lacking  miR‐155  show  impaired  immune  responses, 
whereas  mice  over‐expressing  miR‐155  exhibit  perturbed  peripheral  blood  cell 
populations  [216,219].  Mice  deficient  for  the  miR‐17‐92  cluster  die  directly  after  birth, 
showing  hypoplastic  lungs  and  reduced  amounts  of  pre‐B‐cells.  Conversely,  mice  with 
enhanced  expression  of  miR‐17‐92  in  lymphocytes  exhibit  a  lymphoproliferative 
phenotype coupled with autoimmunity and premature death [5,230]. These observations 
suggest  miRNAs  as  important  regulators  that  control  normal  development  and 
homeostasis. Knowing this, it is astonishing that data from this study and also from other 
groups  show  that miRNAs have  a  very  limited  impact  on  the  expression  levels  of  their 
target mRNAs  and proteins  [264].  Indeed, miRNAs  are believed  to  act  as  switches  and 
fine‐tuners  of  target  genes with  dependence  on  the mRNA  expression  levels  [263].  In 
general,  the  interaction of a single miRNA with a single target mRNA might not explain 
the  observed  phenotypes.  Rather  the  tightly  coordinated  regulation  of  many  target 
genes  as  for  instance  suggested  by  Linsley  and  colleagues  [289]  and  the  mutual 
modulation and control of miRNAs and mRNAs [290], including feedback loops [291,292] 
(refer  to  1.6.1),  are  responsible  for  keeping  the  balance,  that  prevents  aberrant 
developments.  
It was previously reported that single miRNAs or miRNA clusters act on several positions 
within  a  single  signaling  cascade  or  alternatively  in  functionally  “redundant”  pathways 






up  to  20  of  the  top  30  AGO2‐associated  miRNAs.  Furthermore,  similar  results  were 










10,000 quantified mRNAs were  differentially  expressed.  For  instance, CCND1  or  the ETS 
transcription  factor  sub‐family PEA3  (ETV1, ETV4  and ETV5) were  highly  up  regulated  in 
HEK‐miR‐155  cells.  PEA3  genes  ETV4  and  ETV5  were  shown  involved  in  kidney 
development  [294].  Furthermore,  over‐expression  of  PEA3  gene  family  members  was 





of  a  tightly  controlled  miRNA‐mRNA  interaction  network,  as  previously  proposed  by 
other  groups  [290].  Deforming  this  network  by  ectopic  expression  of  single  miRNAs 
might  result  in  and  explain  changes  in  cellular  phenotypes.  Furthermore,  the  miRNA 
biogenesis is a tightly regulated process as described in section 1.6. RIP‐Seq of JEKO‐1 and 
MEC‐1 showed that several  factors of  the biogenesis pathway are  regulated by miRNAs 
themselves  in  negative  feedback  loops.  Recently,  it  was  shown  that  pseudogenes  and 
competing  endogenous  RNAs  (ceRNA)  are  of  relevance  for  modulating  the  activity  of 
miRNAs  within  cells,  suggesting  their  involvement  in  fine‐tuning  of  the  fine  tuners 
[296,297]. 
4.4 Disproportional association of miRNAs to AGO2 








In  the  presented  work,  miRNA  specific  TaqMan  arrays  were  used  to  generate  miRNA 
expression  profiles  of  those  cells  tested  by  RIP‐Seq.  In  addition,  an  activity  profile  of 
miRNAs was obtained simultaneously by quantifying miRNAs that co‐IP with AGO2. The 
comparison of  these  two data  sets allowed  to  investigate whether all miRNAs  that are 
expressed in cells are equally frequent bound to AGO2 and therefore active. Interestingly, 
this comparison revealed that several miRNAs,  including miR‐155 and miR‐17, were over‐
proportionally  associated  with  AGO2.  Strikingly,  similar  results  were  obtained  with 
HEK293T  cells  and  the  two B  cell  lines,  suggesting  that  among others, miR‐155, miR‐17, 
miR‐20a and miR‐92a‐1  are  recurrently over‐represented  in AGO2‐containing  complexes. 
Furthermore,  these  results  are  in  line  with  a  published  study  using  embryonic  and 




additional  technical  replicates  have  to  be  performed  to  obtain  robust  statistics  for  the 
data,  before  firm  conclusions  can  be  drawn.  Furthermore  the  mechanisms  potentially 
leading to this observed effect are unknown so far. 




Screening  for  miRNA  targets  in  HEK293T,  JEKO‐1  and  MEC‐1  cells  using  the  RIP‐Seq 
method  identified hundreds of protein  coding genes presumably  regulated by miRNAs. 
To  analyze  the  co‐precipitated  RNAs  after  RIP,  sequencing  libraries  were  generated 
applying poly(A) enrichment  in order  to deplete ribosomal RNAs (rRNA). Since the vast 
majority of non‐coding RNAs  is not poly‐adenylated,  these  fractions were not analyzed. 
However,  recent  publications  suggest  that  non‐coding  RNAs  are  also  regulated  by 
miRNAs  and  then  in  turn  might  modulate  miRNA  activities  on  protein  coding  genes 












the development of  leukemias and  lymphomas. With regard to the results of  this study 
and  previous  findings  by  others  [290,293],  miRNAs  act  in  networks  simultaneously 
regulating  thousands  of  genes,  suggesting  that multiple miRNA‐mRNA  interactions  are 
leading to phenotypic changes. RIP‐Seq analysis of the B‐cell lymphoma lines JEKO‐1 and 
MEC‐1 revealed more than hundred genes potentially regulated by miR‐155 and the miR‐
17‐92  cluster  (e.g.  ZFP36).  In  order  to  identify  those  targets  with  pathomechanistic 
relevance, the dataset needs to be extended to a cohort of patients to identify commonly 
regulated miRNA targets. Furthermore, the RIP‐Seq experiments of the presented work 
suggested  a  cooperative  activity  of  multiple  miRNAs  on  single  targets.  Thus,  the 
identification  of  such  target  genes  that  are  cooperatively  regulated  by  miRNAs  (e.g. 
BTG2),  especially  if  an  association  of  these miRNAs with  cancer was  already  described 
(e.g. miR‐34a or miR‐21), might  lead  to  the discovery of genes with  relevance  in CLL or 
MCL. 
4.5.3 Disproportional association of miRNAs with AGO2  
In  the  present  study,  RIP‐Seq  experiments  revealed  a  disproportional  enrichment  of 
miRNAs, including miR‐155, miR‐92a‐1 and miR‐320, in the AGO2 IP fractions. However, the 
lack of biological and technical replicates is a drawback so far. Interestingly, the general 
phenomenon was  recurrently  described  by  another  group,  identifying  several miRNAs, 





no prevalent  association of  specific miRNAs  to  single AGO proteins,  indicating  that  the 
disproportional loading could be a general feature [147]. 
The mechanism(s)  responsible  for  these  findings  remain  elusive.  Feasible  explanations 
are variations in AGO2‐miRNA stabilities [307], different miRNA accessibilities due to sub‐
cellular  distribution  [308],  miRNA  specific  AGO2  loading  efficiencies  or  the  differential 
expression of co‐factors involved in miRNA loading processes.  
Taken  together  these data  indicate  that  the activity of certain miRNAs, which are over‐
proportionally associated with AGO2, is higher than suggested by their expression levels. 
It  thus  remains  to  be  tested,  whether  these  observations  are  de  facto  reflected  by  a 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Table  S  1: Summary  of mapped  and  quantified  reads  per  sample  and  replicate  of HEK‐
vector and pREP4miR‐155 generated by 2nd generation sequencing 




HEK‐vector  IP  1  38847512  26697792  68.72 
HEK‐vector  IP  2  35200455  24681908  70.12 
HEK‐vector  IP  3  34633980  24064313  69.48 
HEK‐vector  TL  1  77647039  56479074  72.74 
HEK‐vector  TL  2  51827659  38276456  73.85 
HEK‐vector  TL  3  66831196  48956322  73.25 
HEK‐miR‐155  IP  1  33679129  23334445  69.28 
HEK‐miR‐155  IP  2  34442706  24432299  70.94 
HEK‐miR‐155  IP  3  35082010  24734154  70.50 
HEK‐miR‐155  TL  1  69955916  50830568  72.66 
HEK‐miR‐155  TL  2  71385945  53103311  74.39 
HEK‐miR‐155  TL  3  72132189  53445065  74.09 
 
Table S 2: List of significantly (p<0.05) enriched mRNAs in HEK‐miR‐155 compared to the 
IP  of  HEK‐vector  (n=  213).  Genes  predicted  for  being  miR‐155  targets  (according  to 
MiRWalk) are marked with bold letters. 
Gene  Log2‐FC  P‐value    Gene  Log2‐FC  P‐value 
TNFRSF11B  6,10E+00  7,99E‐17    NDUFAF2  6,54E‐01  1,16E‐02 
FAM78A  1,78E+00  4,29E‐16    MRPS18C  6,69E‐01  1,19E‐02 
KCNQ2  1,59E+00  2,20E‐15    ELOVL6  6,59E‐01  1,21E‐02 
C21orf37  5,59E+00  7,51E‐11    RGS3  7,58E‐01  1,26E‐02 
CCND1  3,88E+00  1,03E‐10    SYNPO  9,38E‐01  1,28E‐02 
DPYSL3  1,55E+00  5,27E‐10    EFNA3  7,07E‐01  1,29E‐02 
TCF4  1,32E+00  5,38E‐10    FBXO9  6,38E‐01  1,38E‐02 
ALDH1A2  1,23E+00  2,65E‐09    NDUFC1  6,33E‐01  1,48E‐02 
ZNF483  1,92E+00  2,65E‐09    TCF7L2  6,52E‐01  1,48E‐02 
CA12  1,36E+00  4,84E‐09    MMP2  1,15E+00  1,51E‐02 
AGTRAP  1,20E+00  7,32E‐09    ANAPC5  6,41E‐01  1,53E‐02 
COL27A1  1,20E+00  2,67E‐08    CHCHD7  6,44E‐01  1,53E‐02 
LY6E  1,04E+00  9,23E‐07    UROS  6,20E‐01  1,54E‐02 
C12orf39  1,33E+00  1,53E‐06    IMPDH1  6,23E‐01  1,59E‐02 
FAM84B  1,02E+00  1,62E‐06    C17orf96  6,43E‐01  1,64E‐02 
BMP2  2,18E+00  3,28E‐06    EXOSC4  8,37E‐01  1,65E‐02 
PROCR  1,08E+00  3,88E‐06    ABCE1  6,23E‐01  1,67E‐02 
NDRG1  1,15E+00  3,96E‐06    KLRG2  6,96E‐01  1,70E‐02 
OR2V2  5,02E+00  5,36E‐06    NRARP  6,23E‐01  1,78E‐02 
C19orf51  1,06E+00  1,19E‐05    APRT  6,01E‐01  1,81E‐02 
PNPT1  8,90E‐01  8,07E‐05    NELL1  4,33E+00  1,84E‐02 
COTL1  8,89E‐01  9,17E‐05    PDZRN3  7,83E‐01  1,86E‐02 
EDA2R  3,64E+00  9,25E‐05    CHRNA4  1,54E+00  1,89E‐02 
USPL1  9,02E‐01  9,25E‐05    GNG4  6,04E‐01  1,91E‐02 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PPA2  8,75E‐01  9,25E‐05    CHAC2  6,48E‐01  1,93E‐02 
FCRLB  1,46E+00  9,25E‐05    CKMT1A  9,27E‐01  1,93E‐02 
HMOX1  1,01E+00  1,50E‐04    NDUFA8  6,28E‐01  1,99E‐02 
SOD1  8,45E‐01  1,66E‐04    UQCRFS1  6,23E‐01  2,01E‐02 
TRMT12  8,80E‐01  2,39E‐04    CDC42EP4  6,41E‐01  2,01E‐02 
ZNF813  1,59E+00  2,71E‐04    PRPS2  6,12E‐01  2,01E‐02 
BBS7  8,74E‐01  2,79E‐04    AL050321.1  9,73E‐01  2,01E‐02 
PHC2  1,50E+00  3,21E‐04    MARS2  6,33E‐01  2,01E‐02 
CHST15  8,55E‐01  3,25E‐04    GABRD  9,27E‐01  2,07E‐02 
FAM150A  2,24E+00  3,26E‐04    DUSP14  6,46E‐01  2,21E‐02 
ALPL  9,46E‐01  3,88E‐04    TPRKB  6,04E‐01  2,25E‐02 
C3orf18  8,89E‐01  4,24E‐04    GPRIN3  7,97E‐01  2,31E‐02 
ADCYAP1R1  8,63E‐01  6,47E‐04    FAM179A  1,44E+00  2,34E‐02 
POLR3G  1,02E+00  7,08E‐04    MRPS12  6,27E‐01  2,36E‐02 
FAM49B  7,94E‐01  7,91E‐04    HRSP12  6,17E‐01  2,36E‐02 
TESC  9,80E‐01  8,36E‐04    SEH1L  6,14E‐01  2,37E‐02 
MECR  7,88E‐01  8,53E‐04    ISM2  8,18E‐01  2,37E‐02 
THEM4  7,73E‐01  9,61E‐04    BOP1  6,51E‐01  2,38E‐02 
INTS10  7,84E‐01  1,01E‐03    LRIF1  6,14E‐01  2,38E‐02 
C8orf33  7,66E‐01  1,20E‐03    ETV5  1,92E+00  2,38E‐02 
VAMP3  7,53E‐01  1,30E‐03    DCTD  5,95E‐01  2,40E‐02 
SPRED1  8,30E‐01  1,37E‐03    EGLN3  6,66E‐01  2,50E‐02 
TBC1D14  7,60E‐01  1,49E‐03    TSKU  6,28E‐01  2,51E‐02 
ARSJ  1,01E+00  1,52E‐03    CTSC  6,00E‐01  2,52E‐02 
ADA  8,15E‐01  1,82E‐03    PRR5L  8,74E‐01  2,61E‐02 
MRPL13  7,48E‐01  1,96E‐03    LSM4  5,89E‐01  2,67E‐02 
ETV1  1,38E+00  1,98E‐03    HSPD1  5,79E‐01  2,68E‐02 
BCL6B  7,82E‐01  2,02E‐03    EYA2  7,07E‐01  2,69E‐02 
EIF2C2  9,18E‐01  2,24E‐03    ZNF85  1,49E+00  2,69E‐02 
KHDRBS3  7,73E‐01  2,25E‐03    PPID  6,10E‐01  2,69E‐02 
METTL21A  7,54E‐01  2,26E‐03    WDR77  6,01E‐01  2,81E‐02 
ZNF586  1,09E+00  2,51E‐03    MAP2K6  6,31E‐01  2,95E‐02 
DET1  1,48E+00  2,61E‐03    LSM12  5,77E‐01  2,95E‐02 
LIPT1  7,88E‐01  2,61E‐03    GTF2E2  6,07E‐01  2,96E‐02 
COPS2  6,98E‐01  2,66E‐03    OR7D2  1,93E+00  2,96E‐02 
SPRY1  7,84E‐01  2,82E‐03    TNFRSF10D  7,19E‐01  2,99E‐02 
EPHA8  1,32E+00  3,25E‐03    SLC25A33  6,02E‐01  2,99E‐02 
TRIM32  7,40E‐01  3,38E‐03    RPL17  9,59E‐01  2,99E‐02 
FBXO32  8,60E‐01  3,56E‐03    OAF  5,93E‐01  3,06E‐02 
DSCC1  7,02E‐01  3,86E‐03    PVRL4  1,55E+00  3,18E‐02 
ARRDC2  7,77E‐01  3,89E‐03    TMEM177  5,84E‐01  3,21E‐02 
TSTA3  7,19E‐01  3,93E‐03    WDYHV1  6,33E‐01  3,21E‐02 
IER5  7,41E‐01  3,95E‐03    TMEM14B  5,86E‐01  3,30E‐02 
C20orf27  7,05E‐01  4,03E‐03    SLC25A32  6,13E‐01  3,32E‐02 
TATDN3  7,07E‐01  4,05E‐03    SLC25A4  6,06E‐01  3,35E‐02 
PYCRL  7,96E‐01  4,19E‐03    NEIL2  6,21E‐01  3,40E‐02 
TATDN1  7,12E‐01  4,37E‐03    QPRT  8,78E‐01  3,40E‐02 
HOMEZ  7,35E‐01  4,51E‐03    ACN9  5,95E‐01  3,42E‐02 
C12orf24  6,99E‐01  4,58E‐03    RASGEF1A  6,08E‐01  3,56E‐02 
CHRAC1  6,92E‐01  4,64E‐03    ZNF44  8,05E‐01  3,56E‐02 
UAP1  6,91E‐01  4,69E‐03    MRPS18A  5,93E‐01  3,57E‐02 
SLIRP  6,95E‐01  4,69E‐03    CHEK2  5,83E‐01  3,57E‐02 
DCK  7,09E‐01  4,69E‐03    RRP7A  5,78E‐01  3,57E‐02 
SLC11A1  1,59E+00  4,71E‐03    LSM6  5,95E‐01  3,64E‐02 
ATP1A3  7,31E‐01  4,89E‐03    SRXN1  5,81E‐01  3,66E‐02 
EID2  7,31E‐01  5,03E‐03    SNCB  1,02E+00  3,68E‐02 
STAP2  1,36E+00  5,24E‐03    RNF139  6,69E‐01  3,68E‐02 
CYC1  7,69E‐01  5,47E‐03    WNT10B  6,49E‐01  3,68E‐02 
GLRX5  6,92E‐01  5,55E‐03    FRAT2  5,71E‐01  3,98E‐02 
PLCD3  6,88E‐01  5,98E‐03    MLF1IP  5,54E‐01  4,02E‐02 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MT1X  7,72E‐01  6,08E‐03    TMEM145  6,91E‐01  4,08E‐02 
CACYBP  6,90E‐01  6,15E‐03    SH2D5  6,86E‐01  4,08E‐02 
ETV4  2,26E+00  6,51E‐03    RIMS4  5,89E‐01  4,13E‐02 
PFN2  6,65E‐01  6,87E‐03    FGFR4  6,04E‐01  4,23E‐02 
EXT1  6,82E‐01  7,23E‐03    RABEPK  5,84E‐01  4,24E‐02 
EEF1E1  6,76E‐01  7,42E‐03    BEND4  6,20E‐01  4,33E‐02 
TADA2B  6,78E‐01  7,79E‐03    FAM155B  5,81E‐01  4,33E‐02 
HSPE1  6,82E‐01  7,81E‐03    METTL5  5,66E‐01  4,33E‐02 
MYCL1  6,89E‐01  8,27E‐03    CENPV  5,58E‐01  4,33E‐02 
NCS1  6,71E‐01  8,68E‐03    IKBKE  7,65E‐01  4,35E‐02 
TRIP13  6,63E‐01  8,90E‐03    PRDX4  5,54E‐01  4,41E‐02 
DHRS2  1,12E+00  9,69E‐03    SPRED2  5,82E‐01  4,63E‐02 
FXN  6,64E‐01  9,89E‐03    ISCA1  5,49E‐01  4,68E‐02 
C3orf14  6,48E‐01  1,00E‐02    COL14A1  1,05E+00  4,73E‐02 
C1orf124  6,61E‐01  1,01E‐02    TSHZ3  5,54E‐01  4,77E‐02 
PANK1  6,69E‐01  1,01E‐02    POP1  5,98E‐01  4,87E‐02 
SRD5A3  6,59E‐01  1,02E‐02    DFFA  5,39E‐01  4,87E‐02 
CEBPB  1,44E+00  1,02E‐02    TOP1MT  5,55E‐01  4,87E‐02 
ZFP36  7,78E‐01  1,02E‐02    NOP16  5,71E‐01  4,92E‐02 
UBE2V2  7,77E‐01  1,03E‐02    PNO1  5,60E‐01  4,92E‐02 
ATP6V1E2  7,22E‐01  1,03E‐02    GPATCH4  5,56E‐01  4,92E‐02 
GAL  6,68E‐01  1,10E‐02    WDR67  5,57E‐01  4,92E‐02 




Gene  Log2‐FC  P‐value    Gene  Log2‐FC  P‐value 
SPARC  ‐4.70E+00  3.71E‐27    NMI  ‐1.10E+00  8.68E‐03 
GALNT13  ‐2.84E+00  6.11E‐26    ZNF536  ‐1.03E+00  8.68E‐03 
EPAS1  ‐2.26E+00  1.28E‐22    OPHN1  ‐8.33E‐01  8.90E‐03 
DOK6  ‐3.79E+00  1.47E‐22    ABCA3  ‐1.15E+00  8.90E‐03 
COL2A1  ‐2.47E+00  6.07E‐20    SLC13A4  ‐1.03E+00  9.21E‐03 
ULK2  ‐2.06E+00  2.41E‐19    HEATR5B  ‐7.11E‐01  9.25E‐03 
UBE2QL1  ‐2.71E+00  2.56E‐18    HOXB3  ‐6.99E‐01  9.25E‐03 
CDO1  ‐4.58E+00  8.50E‐17    SLFN5  ‐1.46E+00  9.25E‐03 
CYP26B1  ‐2.26E+00  1.06E‐16    NME5  ‐1.82E+00  9.32E‐03 
PCDH10  ‐1.68E+00  3.30E‐15    CBLB  ‐8.34E‐01  9.43E‐03 
ZFP106  ‐1.54E+00  1.99E‐13    FZD10  ‐1.32E+00  9.69E‐03 
PGCP  ‐3.57E+00  2.24E‐12    DMRTA2  ‐1.78E+00  9.69E‐03 
FAM20C  ‐1.62E+00  9.82E‐12    CAV1  ‐9.52E‐01  1.00E‐02 
OAS3  ‐4.48E+00  1.95E‐11    TTC28  ‐6.87E‐01  1.03E‐02 
EHBP1L1  ‐1.84E+00  7.74E‐11    GOLGA2  ‐7.04E‐01  1.03E‐02 
STARD9  ‐1.50E+00  7.74E‐11    LRRC57  ‐7.03E‐01  1.05E‐02 
TTBK2  ‐1.61E+00  1.35E‐10    PLXNA4  ‐3.18E+00  1.06E‐02 
MAMLD1  ‐1.74E+00  1.60E‐10    RALGAPA2  ‐6.94E‐01  1.09E‐02 
CDH2  ‐1.95E+00  6.45E‐10    IFI27L2  ‐7.54E‐01  1.10E‐02 
OPTN  ‐1.30E+00  1.78E‐09    NEK11  ‐1.12E+00  1.10E‐02 
MYO5B  ‐1.97E+00  1.78E‐09    SCAPER  ‐7.45E‐01  1.11E‐02 
PLA2G4A  ‐3.32E+00  2.65E‐09    CADPS2  ‐1.32E+00  1.13E‐02 
APH1B  ‐1.36E+00  2.65E‐09    GAP43  ‐1.71E+00  1.14E‐02 
SLIT2  ‐1.19E+00  4.11E‐09    SCN8A  ‐1.02E+00  1.14E‐02 
FGF13  ‐2.68E+00  7.32E‐09    HERC1  ‐7.10E‐01  1.15E‐02 
DMRT3  ‐3.94E+00  1.17E‐08    KIAA0889  ‐6.92E‐01  1.15E‐02 
VPS39  ‐1.18E+00  2.67E‐08    SLC2A10  ‐7.85E‐01  1.17E‐02 
OSBPL7  ‐1.88E+00  8.23E‐08    STAT3  ‐6.51E‐01  1.18E‐02 
Supplementary  
 124 
Gene  Log2‐FC  P‐value    Gene  Log2‐FC  P‐value 
DDIT4L  ‐1.92E+00  1.61E‐07    PLCL1  ‐1.46E+00  1.19E‐02 
GANC  ‐1.37E+00  1.87E‐07    ANG  ‐1.56E+00  1.19E‐02 
LRP1  ‐1.19E+00  2.38E‐07    CBX5  ‐6.50E‐01  1.21E‐02 
CDAN1  ‐1.21E+00  2.62E‐07    MAP6  ‐1.10E+00  1.21E‐02 
PVALB  ‐2.88E+00  4.56E‐07    IGF2R  ‐6.49E‐01  1.22E‐02 
PRKCB  ‐1.34E+00  4.67E‐07    PAK3  ‐1.95E+00  1.26E‐02 
TP53INP1  ‐1.23E+00  4.73E‐07    FBN2  ‐6.84E‐01  1.27E‐02 
FBXO27  ‐1.20E+00  5.58E‐07    CXorf58  ‐2.17E+00  1.33E‐02 
ZSCAN29  ‐1.12E+00  5.77E‐07    C8orf42  ‐1.11E+00  1.37E‐02 
UBR1  ‐1.13E+00  6.99E‐07    SBNO1  ‐6.58E‐01  1.39E‐02 
CCNDBP1  ‐1.17E+00  8.57E‐07    ABCB4  ‐1.98E+00  1.39E‐02 
WNT9A  ‐1.59E+00  8.57E‐07    C19orf57  ‐8.36E‐01  1.48E‐02 
AIFM2  ‐2.02E+00  9.38E‐07    CELSR2  ‐6.73E‐01  1.50E‐02 
SAMD12  ‐1.56E+00  1.53E‐06    RNF175  ‐2.16E+00  1.52E‐02 
NACAD  ‐1.50E+00  2.22E‐06    PLD1  ‐1.07E+00  1.52E‐02 
TMSB4X  ‐1.57E+00  4.63E‐06    HERC3  ‐7.09E‐01  1.53E‐02 
PLCB2  ‐2.20E+00  5.84E‐06    MLL2  ‐6.23E‐01  1.53E‐02 
KCNQ1  ‐1.42E+00  6.93E‐06    KIAA0913  ‐6.42E‐01  1.53E‐02 
TMEM62  ‐1.13E+00  6.93E‐06    EPSTI1  ‐1.28E+00  1.56E‐02 
TMEM87A  ‐1.04E+00  6.93E‐06    SORT1  ‐6.14E‐01  1.56E‐02 
CELF2  ‐1.68E+00  1.09E‐05    EFTUD1  ‐6.88E‐01  1.64E‐02 
RYR2  ‐2.66E+00  1.09E‐05    ABCA5  ‐7.47E‐01  1.64E‐02 
LCMT2  ‐1.04E+00  1.25E‐05    C12orf51  ‐6.39E‐01  1.64E‐02 
CLVS2  ‐3.75E+00  1.25E‐05    KNTC1  ‐6.50E‐01  1.64E‐02 
HOXA5  ‐1.06E+00  1.28E‐05    PPP1R12B  ‐7.63E‐01  1.65E‐02 
ODZ1  ‐5.34E+00  1.34E‐05    ATF7IP  ‐6.93E‐01  1.65E‐02 
PDE10A  ‐1.41E+00  1.34E‐05    LMLN  ‐7.46E‐01  1.65E‐02 
CACNA1G  ‐1.68E+00  1.37E‐05    PRKCH  ‐8.24E‐01  1.66E‐02 
LMO7  ‐1.07E+00  1.77E‐05    LRRC33  ‐1.12E+00  1.78E‐02 
G0S2  ‐1.84E+00  2.22E‐05    KANK1  ‐6.96E‐01  1.79E‐02 
OTX2  ‐1.59E+00  2.44E‐05    SYTL4  ‐8.30E‐01  1.81E‐02 
STXBP5L  ‐2.18E+00  3.24E‐05    PGPEP1  ‐6.89E‐01  1.81E‐02 
IQGAP3  ‐9.85E‐01  3.25E‐05    INSR  ‐7.89E‐01  1.83E‐02 
KCTD12  ‐9.82E‐01  3.75E‐05    NMU  ‐7.22E‐01  1.86E‐02 
MAP7  ‐9.87E‐01  4.98E‐05    DDAH2  ‐7.19E‐01  1.86E‐02 
ST8SIA4  ‐3.65E+00  5.99E‐05    SAMD5  ‐9.60E‐01  1.87E‐02 
EFEMP2  ‐1.83E+00  6.79E‐05    MYO3A  ‐1.11E+00  1.93E‐02 
SNAP91  ‐1.74E+00  6.80E‐05    APBA1  ‐1.39E+00  1.93E‐02 
SLC16A5  ‐4.61E+00  6.85E‐05    NTNG1  ‐3.13E+00  1.93E‐02 
SLC35F3  ‐2.71E+00  6.91E‐05    RASGRP1  ‐1.03E+00  1.93E‐02 
GPRC5C  ‐1.47E+00  8.07E‐05    LTK  ‐9.18E‐01  1.94E‐02 
TUBGCP4  ‐9.67E‐01  8.08E‐05    SLC17A5  ‐6.47E‐01  1.94E‐02 
ADAL  ‐9.79E‐01  8.57E‐05    SZT2  ‐7.14E‐01  2.01E‐02 
AC010336.1  ‐1.78E+00  8.57E‐05    ANTXR2  ‐8.25E‐01  2.06E‐02 
OCLN  ‐1.01E+00  8.57E‐05    SLC46A3  ‐7.09E‐01  2.06E‐02 
SNAP23  ‐9.04E‐01  8.67E‐05    ALG1L  ‐1.05E+00  2.07E‐02 
FREM2  ‐1.23E+00  9.17E‐05    DOCK8  ‐9.09E‐01  2.09E‐02 
B3GALT1  ‐1.92E+00  9.43E‐05    PHIP  ‐6.87E‐01  2.11E‐02 
LONRF2  ‐1.08E+00  9.54E‐05    SRCAP  ‐5.99E‐01  2.14E‐02 
APOBEC3B  ‐1.86E+00  9.86E‐05    PARD3B  ‐8.67E‐01  2.14E‐02 
LAMB2  ‐9.14E‐01  1.03E‐04    YPEL5  ‐7.61E‐01  2.14E‐02 
THRB  ‐1.01E+00  1.09E‐04    PTPN14  ‐7.53E‐01  2.14E‐02 
DCHS1  ‐1.40E+00  1.10E‐04    ZNF396  ‐9.41E‐01  2.14E‐02 
BEX2  ‐8.93E‐01  1.10E‐04    C2orf72  ‐7.30E‐01  2.18E‐02 
SLITRK5  ‐9.34E‐01  1.10E‐04    DKK3  ‐9.09E‐01  2.21E‐02 
SPINT2  ‐1.34E+00  1.48E‐04    GOLGB1  ‐8.13E‐01  2.22E‐02 
TTLL7  ‐1.02E+00  1.48E‐04    AFF3  ‐6.75E‐01  2.24E‐02 
MBP  ‐1.58E+00  1.50E‐04    MAP1A  ‐1.48E+00  2.24E‐02 
NKAIN2  ‐2.57E+00  1.50E‐04    GPX3  ‐5.99E‐01  2.25E‐02 
PRRX1  ‐2.19E+00  1.58E‐04    MAP2  ‐1.81E+00  2.27E‐02 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GPR126  ‐1.56E+00  1.59E‐04    EGR2  ‐1.42E+00  2.31E‐02 
RAB9B  ‐1.11E+00  2.42E‐04    SERPING1  ‐2.19E+00  2.34E‐02 
NPY1R  ‐5.47E+00  2.45E‐04    DIAPH3  ‐6.52E‐01  2.37E‐02 
CALCOCO1  ‐9.32E‐01  2.66E‐04    VGLL2  ‐1.03E+00  2.37E‐02 
HIP1  ‐8.63E‐01  2.88E‐04    TRIB2  ‐7.27E‐01  2.38E‐02 
SPEN  ‐8.13E‐01  3.00E‐04    LIG4  ‐6.51E‐01  2.38E‐02 
MCOLN3  ‐1.04E+00  3.05E‐04    SYNJ1  ‐6.30E‐01  2.40E‐02 
FSTL1  ‐8.40E‐01  3.26E‐04    EXOC6B  ‐6.33E‐01  2.47E‐02 
RAI2  ‐1.24E+00  3.69E‐04    SDK1  ‐7.43E‐01  2.51E‐02 
PRKG2  ‐3.28E+00  3.77E‐04    RIMBP3  ‐2.38E+00  2.51E‐02 
DNAH11  ‐1.50E+00  4.01E‐04    AMOTL2  ‐7.17E‐01  2.51E‐02 
SYT1  ‐1.02E+00  4.42E‐04    IQGAP1  ‐6.16E‐01  2.51E‐02 
MNS1  ‐1.50E+00  4.48E‐04    ARL10  ‐5.98E‐01  2.51E‐02 
NES  ‐2.08E+00  4.63E‐04    GALC  ‐8.94E‐01  2.52E‐02 
FRAS1  ‐9.05E‐01  4.71E‐04    SMC4  ‐6.18E‐01  2.55E‐02 
PARP9  ‐1.22E+00  4.84E‐04    DAPK1  ‐6.17E‐01  2.57E‐02 
LGR5  ‐1.24E+00  5.36E‐04    TAP1  ‐6.30E‐01  2.58E‐02 
HSBP1L1  ‐1.62E+00  5.49E‐04    CYBRD1  ‐7.84E‐01  2.61E‐02 
TMSB15A  ‐8.47E‐01  5.61E‐04    MYO7A  ‐3.57E+00  2.64E‐02 
LRRN2  ‐1.50E+00  5.76E‐04    LBH  ‐9.74E‐01  2.66E‐02 
CA8  ‐2.74E+00  7.65E‐04    BAI3  ‐8.79E‐01  2.67E‐02 
FOSL2  ‐1.07E+00  7.71E‐04    BCL6  ‐7.79E‐01  2.68E‐02 
LPL  ‐2.67E+00  7.71E‐04    C7orf46  ‐8.59E‐01  2.68E‐02 
DUSP10  ‐9.25E‐01  7.73E‐04    SLC44A5  ‐6.37E‐01  2.69E‐02 
CUL9  ‐8.66E‐01  7.82E‐04    BICC1  ‐6.35E‐01  2.83E‐02 
ANKRD1  ‐1.43E+00  7.91E‐04    ARHGAP33  ‐6.85E‐01  2.85E‐02 
LGALS1  ‐9.18E‐01  8.20E‐04    SLC22A23  ‐6.30E‐01  2.89E‐02 
BRSK1  ‐9.49E‐01  8.33E‐04    ARHGAP31  ‐7.40E‐01  2.95E‐02 
LYPD6  ‐8.21E‐01  8.39E‐04    FAM65B  ‐1.66E+00  2.95E‐02 
FAT3  ‐1.21E+00  8.46E‐04    ARHGAP27  ‐7.90E‐01  2.95E‐02 
CAMK4  ‐1.12E+00  8.51E‐04    HDX  ‐8.43E‐01  2.96E‐02 
ADAMTSL3  ‐2.54E+00  8.53E‐04    ARMCX4  ‐7.74E‐01  2.96E‐02 
ODZ4  ‐1.75E+00  9.14E‐04    RGS7  ‐1.15E+00  3.01E‐02 
AHR  ‐1.04E+00  9.14E‐04    DST  ‐6.06E‐01  3.02E‐02 
DGKA  ‐9.66E‐01  9.57E‐04    TKTL1  ‐1.65E+00  3.13E‐02 
HOXA4  ‐1.17E+00  9.60E‐04    GPC5  ‐1.44E+00  3.13E‐02 
CXCL12  ‐6.49E+00  9.72E‐04    RAPGEF5  ‐7.89E‐01  3.17E‐02 
ATP9A  ‐7.89E‐01  9.76E‐04    RFX6  ‐1.93E+00  3.28E‐02 
MFSD6  ‐1.36E+00  9.80E‐04    NCKAP5L  ‐6.12E‐01  3.29E‐02 
C8orf4  ‐4.56E+00  1.00E‐03    MDGA1  ‐6.45E‐01  3.32E‐02 
HOXA6  ‐1.53E+00  1.01E‐03    COL24A1  ‐1.32E+00  3.40E‐02 
CXCL16  ‐8.57E‐01  1.03E‐03    COLEC12  ‐7.55E‐01  3.43E‐02 
SRRM2  ‐7.65E‐01  1.04E‐03    TOP2A  ‐5.69E‐01  3.44E‐02 
FAM5C  ‐5.47E+00  1.12E‐03    SPOCK3  ‐1.58E+00  3.53E‐02 
ARHGEF17  ‐8.73E‐01  1.19E‐03    CHD7  ‐5.95E‐01  3.56E‐02 
MOB3C  ‐1.10E+00  1.34E‐03    CLSPN  ‐6.03E‐01  3.57E‐02 
CREBBP  ‐7.67E‐01  1.36E‐03    TBC1D5  ‐6.61E‐01  3.57E‐02 
IRS4  ‐7.63E‐01  1.49E‐03    RNASEL  ‐8.67E‐01  3.57E‐02 
MCTP1  ‐1.94E+00  1.52E‐03    AGTR1  ‐1.10E+00  3.57E‐02 
FAM134B  ‐1.01E+00  1.58E‐03    IFITM1  ‐1.18E+00  3.58E‐02 
PLEKHB1  ‐9.16E‐01  1.67E‐03    FRMPD3  ‐8.42E‐01  3.59E‐02 
PLD5  ‐4.92E+00  1.71E‐03    KDM5A  ‐5.78E‐01  3.61E‐02 
EPHB6  ‐2.62E+00  1.82E‐03    CLSTN3  ‐6.39E‐01  3.64E‐02 
CDHR1  ‐1.22E+00  1.88E‐03    RIPK1  ‐5.84E‐01  3.64E‐02 
PTH1R  ‐1.66E+00  1.94E‐03    SYNGAP1  ‐6.82E‐01  3.65E‐02 
NR3C2  ‐8.99E‐01  1.96E‐03    CD109  ‐7.73E‐01  3.66E‐02 
HOXA3  ‐1.01E+00  1.96E‐03    MYO5C  ‐7.17E‐01  3.67E‐02 
KCNT2  ‐2.55E+00  1.98E‐03    RNF144B  ‐9.65E‐01  3.67E‐02 
PLEKHA7  ‐9.72E‐01  2.10E‐03    ACVR1C  ‐1.67E+00  3.68E‐02 
SLIT3  ‐1.32E+00  2.11E‐03    FGF12  ‐2.56E+00  3.68E‐02 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CTTNBP2  ‐9.26E‐01  2.16E‐03    TCN2  ‐2.64E+00  3.69E‐02 
ANK1  ‐2.69E+00  2.23E‐03    FBN1  ‐6.99E‐01  3.73E‐02 
SLC12A6  ‐9.55E‐01  2.33E‐03    MBD5  ‐6.31E‐01  3.74E‐02 
MED12  ‐7.72E‐01  2.41E‐03    PRKCSH  ‐5.82E‐01  3.78E‐02 
ITGA6  ‐8.36E‐01  2.58E‐03    EFNB3  ‐5.96E‐01  3.84E‐02 
MXD1  ‐8.09E‐01  2.67E‐03    DNAJC6  ‐6.44E‐01  3.84E‐02 
SPTB  ‐1.09E+00  2.84E‐03    LHX8  ‐8.29E‐01  3.85E‐02 
PPP1R15A  ‐8.63E‐01  2.84E‐03    CDKL5  ‐9.56E‐01  3.85E‐02 
SPTAN1  ‐7.31E‐01  2.91E‐03    PROX1  ‐1.02E+00  3.91E‐02 
ITGA8  ‐8.03E‐01  2.94E‐03    HIF1A  ‐5.81E‐01  4.04E‐02 
QPCT  ‐1.20E+00  2.96E‐03    ASH1L  ‐5.75E‐01  4.07E‐02 
CXCR4  ‐1.87E+00  3.02E‐03    KIAA1539  ‐7.25E‐01  4.15E‐02 
BASP1  ‐2.46E+00  3.10E‐03    PLXNA3  ‐5.98E‐01  4.17E‐02 
DOCK9  ‐7.75E‐01  3.12E‐03    PNPLA8  ‐8.55E‐01  4.17E‐02 
PKIB  ‐1.09E+00  3.12E‐03    TFAP2A  ‐6.24E‐01  4.20E‐02 
DYSF  ‐2.20E+00  3.12E‐03    C7orf13  ‐1.18E+00  4.24E‐02 
FLT3  ‐2.17E+00  3.12E‐03    EBF4  ‐6.90E‐01  4.25E‐02 
CLSTN2  ‐3.42E+00  3.15E‐03    C5orf42  ‐6.20E‐01  4.29E‐02 
AS3MT  ‐8.31E‐01  3.21E‐03    MAN1C1  ‐8.29E‐01  4.31E‐02 
CACNA2D3  ‐9.55E‐01  3.21E‐03    MAGI1  ‐7.91E‐01  4.32E‐02 
L3MBTL4  ‐1.36E+00  3.21E‐03    KAT6B  ‐5.87E‐01  4.33E‐02 
MTMR11  ‐1.12E+00  3.25E‐03    RAD54L2  ‐5.87E‐01  4.33E‐02 
KIF13B  ‐9.17E‐01  3.38E‐03    KIF14  ‐6.03E‐01  4.34E‐02 
KIF1A  ‐2.18E+00  3.75E‐03    DNMBP  ‐6.14E‐01  4.35E‐02 
SEMA6A  ‐7.97E‐01  3.84E‐03    TP53BP1  ‐5.83E‐01  4.36E‐02 
TANC2  ‐7.80E‐01  3.84E‐03    FAM71E1  ‐1.02E+00  4.41E‐02 
TTC9  ‐9.66E‐01  3.86E‐03    TP53INP2  ‐6.16E‐01  4.41E‐02 
NMNAT2  ‐1.42E+00  3.89E‐03    SH3D21  ‐9.24E‐01  4.42E‐02 
TMEM132E  ‐2.65E+00  4.15E‐03    CCDC15  ‐8.52E‐01  4.46E‐02 
KIAA1370  ‐9.78E‐01  4.22E‐03    PCDH17  ‐7.70E‐01  4.48E‐02 
ADRB2  ‐1.00E+00  4.22E‐03    MON2  ‐5.96E‐01  4.56E‐02 
DLK2  ‐8.59E‐01  4.36E‐03    BMF  ‐1.31E+00  4.61E‐02 
PLAT  ‐1.25E+00  4.69E‐03    SCD5  ‐6.03E‐01  4.61E‐02 
EP300  ‐7.02E‐01  4.88E‐03    FRY  ‐8.12E‐01  4.62E‐02 
GPM6A  ‐1.09E+00  5.10E‐03    CYP1B1  ‐1.99E+00  4.62E‐02 
BCOR  ‐6.76E‐01  5.37E‐03    YWHAG  ‐5.30E‐01  4.62E‐02 
SIPA1L2  ‐7.48E‐01  5.38E‐03    NOTCH2  ‐5.47E‐01  4.63E‐02 
KIAA1731  ‐7.25E‐01  5.55E‐03    KAT6A  ‐5.59E‐01  4.73E‐02 
ISM1  ‐1.01E+00  6.08E‐03    INPP1  ‐6.93E‐01  4.73E‐02 
TP73  ‐7.25E‐01  6.08E‐03    TAOK1  ‐6.24E‐01  4.73E‐02 
NUP210  ‐8.03E‐01  6.12E‐03    ZZEF1  ‐5.65E‐01  4.77E‐02 
HAUS2  ‐7.21E‐01  6.12E‐03    C15orf42  ‐5.55E‐01  4.77E‐02 
SMARCA1  ‐7.18E‐01  6.36E‐03    ATP1B2  ‐7.67E‐01  4.77E‐02 
POU4F1  ‐7.26E‐01  6.36E‐03    GAS2L3  ‐6.41E‐01  4.77E‐02 
HES1  ‐7.06E‐01  6.68E‐03    NFAT5  ‐5.90E‐01  4.82E‐02 
STAG3  ‐1.75E+00  6.70E‐03    AMOTL1  ‐5.54E‐01  4.82E‐02 
KIAA1407  ‐1.33E+00  6.73E‐03    PTPN21  ‐6.11E‐01  4.84E‐02 
KIAA0355  ‐7.34E‐01  7.17E‐03    NNT  ‐5.69E‐01  4.84E‐02 
CGNL1  ‐1.12E+00  7.44E‐03    ERC1  ‐5.93E‐01  4.87E‐02 
SLAIN1  ‐8.50E‐01  7.44E‐03    VPS13C  ‐6.20E‐01  4.87E‐02 
CHSY3  ‐1.09E+00  7.44E‐03    MYH10  ‐5.54E‐01  4.87E‐02 
BEND5  ‐1.96E+00  7.61E‐03    GFRA1  ‐1.13E+00  4.91E‐02 
TM6SF2  ‐2.03E+00  7.61E‐03    NRP1  ‐5.95E‐01  4.92E‐02 
DOPEY1  ‐7.61E‐01  7.64E‐03    GCA  ‐6.25E‐01  4.92E‐02 
DTX1  ‐3.93E+00  7.90E‐03    ASAP2  ‐6.37E‐01  4.93E‐02 
TSLP  ‐1.30E+00  8.04E‐03    HSPA2  ‐1.24E+00  4.97E‐02 







Gene  Log2‐FC 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SPARC  ‐7,06E+00  7,43E‐52    ATP6V1G1  ‐8,16E‐01  3,25E‐04 
DOK6  ‐4,46E+00  2,05E‐46    BRWD3  ‐8,60E‐01  3,40E‐04 
GALNT13  ‐3,38E+00  1,16E‐43    HMCN1  ‐1,38E+00  1,26E‐02 
RHBDD2  ‐7,30E‐01  1,81E‐02    SLITRK5  ‐8,45E‐01  3,40E‐04 
CDO1  ‐5,51E+00  4,50E‐32    LYST  ‐5,97E‐01  4,72E‐02 
COL2A1  ‐2,56E+00  1,69E‐29    ABHD1  ‐1,12E+00  3,52E‐02 
PLA2G4A  ‐4,57E+00  5,43E‐25    RAPGEF2  ‐8,49E‐01  3,67E‐04 
TKTL1  ‐1,63E+00  1,15E‐02    ZNF652  ‐8,50E‐01  3,91E‐04 
BAIAP3  ‐9,28E‐01  3,91E‐02    IGSF11  ‐3,03E+00  4,00E‐04 
OAS3  ‐4,97E+00  9,60E‐24    GAB3  ‐1,64E+00  4,62E‐04 
EPAS1  ‐2,17E+00  1,09E‐23    EFEMP2  ‐1,62E+00  4,77E‐04 
CALCOCO1  ‐6,93E‐01  1,00E‐02    DTX1  ‐3,42E+00  4,78E‐04 
PGCP  ‐4,30E+00  1,47E‐22    TSLP  ‐9,32E‐01  4,57E‐02 
UBE2QL1  ‐2,74E+00  1,49E‐22    GPR126  ‐1,05E+00  4,78E‐04 
ULK2  ‐1,98E+00  4,64E‐20    NR3C2  ‐8,98E‐01  4,97E‐04 
IKZF2  ‐9,76E‐01  4,25E‐02    GSN  ‐6,77E‐01  2,97E‐02 
DSG2  ‐6,17E‐01  2,00E‐02    CDHR1  ‐9,69E‐01  1,89E‐02 
FGF13  ‐3,05E+00  6,31E‐18    TRIM36  ‐9,26E‐01  5,09E‐04 
ZFP106  ‐1,68E+00  4,16E‐17    FGF9  ‐1,78E+00  5,77E‐04 
ATP9A  ‐6,35E‐01  1,56E‐02    HES1  ‐8,33E‐01  5,82E‐04 
PCDH10  ‐1,65E+00  2,50E‐16    KCNA6  ‐2,64E+00  1,07E‐02 
CYP26B1  ‐1,94E+00  3,86E‐14    TMTC2  ‐1,29E+00  5,83E‐04 
MAMLD1  ‐1,77E+00  4,35E‐14    TMEM86A  ‐8,82E‐01  1,61E‐02 
FAT3  ‐2,08E+00  2,23E‐13    COL4A4  ‐2,14E+00  6,36E‐04 
PRKCB  ‐1,61E+00  1,70E‐12    MFSD6  ‐9,51E‐01  2,36E‐02 
SNCAIP  ‐1,09E+00  2,37E‐02    LAMB2  ‐8,18E‐01  6,53E‐04 
OPTN  ‐1,36E+00  2,79E‐11    HSPB8  ‐1,48E+00  4,50E‐02 
PLCB2  ‐2,78E+00  2,87E‐11    KCNK13  ‐1,21E+00  3,10E‐02 
MGAT4A  ‐5,78E‐01  4,88E‐02    GUCY1A2  ‐1,66E+00  1,28E‐02 
CYBRD1  ‐7,80E‐01  2,37E‐02    IGFBPL1  ‐5,66E+00  7,70E‐04 
CLCN4  ‐1,81E+00  3,68E‐02    AHR  ‐9,12E‐01  8,04E‐04 
PTGS2  ‐3,46E+00  1,87E‐02    GPX3  ‐7,78E‐01  8,04E‐04 
SAMD12  ‐1,69E+00  8,51E‐11    SLC16A5  ‐3,42E+00  8,98E‐04 
FOSL2  ‐7,67E‐01  2,04E‐02    BACH1  ‐6,31E‐01  2,32E‐02 
PLD1  ‐9,16E‐01  4,03E‐02    PCDH1  ‐1,20E+00  2,93E‐02 
B3GALT1  ‐2,23E+00  1,30E‐10    LRRN2  ‐1,32E+00  8,98E‐04 
NES  ‐2,77E+00  2,48E‐10    NMNAT2  ‐1,22E+00  1,00E‐02 
EDIL3  ‐4,31E+00  2,49E‐10    MAP6  ‐1,24E+00  8,98E‐04 
ST8SIA4  ‐3,77E+00  3,70E‐10    JARID2  ‐7,99E‐01  9,35E‐04 
FAM20C  ‐1,46E+00  2,15E‐09    CAMK4  ‐1,04E+00  9,66E‐04 
PPP1R15A  ‐7,31E‐01  1,42E‐02    PPP1R9A  ‐9,75E‐01  3,63E‐02 
CDH2  ‐1,74E+00  2,18E‐09    PINK1  ‐6,42E‐01  2,04E‐02 
STXBP5L  ‐2,22E+00  2,51E‐09    L3MBTL4  ‐1,26E+00  1,00E‐03 
EBF4  ‐7,17E‐01  2,98E‐02    CA8  ‐2,48E+00  1,04E‐03 
YPEL3  ‐9,37E‐01  2,48E‐02    C19orf57  ‐9,75E‐01  1,08E‐03 
EHBP1L1  ‐1,46E+00  7,13E‐09    ISM1  ‐1,02E+00  1,13E‐03 
MYO3A  ‐9,71E‐01  3,09E‐02    TM7SF2  ‐7,81E‐01  1,17E‐03 
MMP11  ‐6,53E‐01  5,00E‐02    SCN1B  ‐1,23E+00  1,18E‐03 
MYO5B  ‐1,60E+00  1,15E‐08    NPY1R  ‐2,92E+00  1,24E‐03 
CELF2  ‐1,97E+00  1,17E‐08    ITGA8  ‐8,05E‐01  1,30E‐03 
RYR2  ‐2,72E+00  1,27E‐08    SLAIN1  ‐9,36E‐01  1,32E‐03 
SLC8A3  ‐2,21E+00  1,77E‐02    TUBGCP4  ‐7,73E‐01  1,39E‐03 
RPS6KA5  ‐6,65E‐01  3,52E‐02    GFI1  ‐7,99E‐01  2,00E‐02 
KCNQ1  ‐1,72E+00  1,82E‐08    LONRF2  ‐8,08E‐01  1,43E‐03 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ESRRG  ‐2,56E+00  2,00E‐08    ANTXR2  ‐7,41E‐01  2,38E‐02 
PRKG2  ‐2,88E+00  2,20E‐08    FSTL1  ‐6,61E‐01  1,03E‐02 
SNPH  ‐6,92E‐01  2,49E‐02    LMOD1  ‐8,31E‐01  2,49E‐02 
JAG1  ‐8,79E‐01  2,65E‐02    ZNF513  ‐6,37E‐01  1,96E‐02 
APH1B  ‐1,24E+00  2,20E‐08    QPCT  ‐1,19E+00  1,47E‐03 
CHRDL1  ‐1,32E+00  1,63E‐02    KLHL32  ‐1,75E+00  1,57E‐03 
SYTL4  ‐6,71E‐01  3,17E‐02    SLC46A3  ‐8,47E‐01  1,65E‐03 
TTBK2  ‐1,23E+00  2,20E‐08    SYT1  ‐8,51E‐01  1,67E‐03 
GALC  ‐1,55E+00  5,19E‐08    CXCL12  ‐6,09E+00  1,79E‐03 
AIFM2  ‐2,15E+00  5,20E‐08    FOXQ1  ‐1,58E+00  4,74E‐02 
FOXF1  ‐6,61E‐01  2,74E‐02    SLC13A4  ‐9,15E‐01  2,51E‐02 
STARD9  ‐1,19E+00  6,24E‐08    PLAT  ‐1,28E+00  1,82E‐03 
SERPING1  ‐3,40E+00  8,57E‐08    MCOLN3  ‐8,39E‐01  1,88E‐03 
BMF  ‐1,44E+00  2,05E‐02    HDX  ‐7,55E‐01  2,26E‐02 
SPINT2  ‐1,72E+00  8,66E‐08    MAP7  ‐7,79E‐01  1,99E‐03 
CCNDBP1  ‐1,20E+00  1,09E‐07    KIF1A  ‐2,26E+00  2,02E‐03 
WNT9A  ‐1,61E+00  1,40E‐07    CXCR4  ‐1,73E+00  2,29E‐03 
DMRT3  ‐2,91E+00  2,34E‐07    PROX1  ‐9,50E‐01  2,38E‐03 
DDIT4L  ‐1,62E+00  2,93E‐07    MAN1C1  ‐9,90E‐01  2,39E‐03 
SNAP91  ‐1,88E+00  3,71E‐07    ADAMTS15  ‐8,46E‐01  3,39E‐02 
CACNA1G  ‐1,58E+00  5,05E‐07    C10orf26  ‐5,69E‐01  3,27E‐02 
C1orf172  ‐4,00E+00  5,24E‐07    KRBA2  ‐2,32E+00  2,43E‐03 
DNAH11  ‐7,99E‐01  5,00E‐02    TMEM132E  ‐2,30E+00  2,68E‐03 
LGALS1  ‐1,18E+00  5,54E‐07    PLEKHA7  ‐6,73E‐01  3,56E‐02 
SLIT2  ‐1,04E+00  6,92E‐07    SLFN5  ‐9,40E‐01  3,28E‐02 
UBR1  ‐1,09E+00  8,39E‐07    PIK3CD  ‐8,07E‐01  2,77E‐03 
EPHB6  ‐1,61E+00  4,37E‐02    DCHS1  ‐9,49E‐01  2,97E‐03 
HSPB1  ‐6,79E‐01  1,24E‐02    MIDN  ‐9,07E‐01  5,00E‐02 
NACAD  ‐1,33E+00  8,42E‐07    CLSTN2  ‐2,73E+00  2,97E‐03 
RGP1  ‐5,63E‐01  4,88E‐02    NPFFR2  ‐3,34E+00  2,99E‐03 
ATRNL1  ‐6,82E‐01  3,07E‐02    ABCA3  ‐1,09E+00  1,40E‐02 
EFNB3  ‐6,17E‐01  3,00E‐02    TAP1  ‐5,99E‐01  4,03E‐02 
NMU  ‐6,88E‐01  2,26E‐02    NPR1  ‐1,99E+00  3,05E‐03 
LCMT2  ‐1,08E+00  1,95E‐06    C18orf1  ‐6,81E‐01  3,44E‐02 
PRRX1  ‐2,33E+00  2,60E‐06    ANG  ‐1,42E+00  3,24E‐03 
HOXA5  ‐1,15E+00  2,60E‐06    MOB3C  ‐9,98E‐01  3,36E‐03 
SOX6  ‐7,06E‐01  2,61E‐02    TAPT1  ‐6,41E‐01  2,32E‐02 
RAI2  ‐1,51E+00  3,01E‐06    VGLL2  ‐9,36E‐01  3,57E‐02 
VPS39  ‐1,01E+00  3,23E‐06    MXD1  ‐7,58E‐01  3,36E‐03 
ODZ1  ‐4,93E+00  3,35E‐06    OCLN  ‐7,49E‐01  3,36E‐03 
SMOC2  ‐4,05E+00  3,27E‐02    MYO7A  ‐3,43E+00  3,36E‐03 
CUL9  ‐6,73E‐01  1,31E‐02    S1PR1  ‐1,03E+00  3,36E‐03 
OSBPL7  ‐1,39E+00  3,80E‐06    THRB  ‐7,70E‐01  3,59E‐03 
TTC9  ‐1,34E+00  4,62E‐06    KCNS3  ‐1,09E+00  2,86E‐02 
SLC27A6  ‐1,14E+00  1,83E‐02    DLK2  ‐7,06E‐01  3,55E‐02 
GPRC5C  ‐1,55E+00  4,91E‐06    BRSK1  ‐8,58E‐01  3,93E‐03 
TRIM23  ‐6,78E‐01  1,42E‐02    TTLL7  ‐7,59E‐01  4,06E‐03 
CDAN1  ‐1,06E+00  5,06E‐06    DPY19L1  ‐6,11E‐01  3,04E‐02 
PLCL1  ‐1,71E+00  5,08E‐06    IQGAP3  ‐7,44E‐01  4,22E‐03 
MBP  ‐1,54E+00  5,08E‐06    FAM131A  ‐7,00E‐01  2,04E‐02 
GCA  ‐6,57E‐01  3,10E‐02    MCTP1  ‐1,24E+00  1,91E‐02 
BEX2  ‐9,82E‐01  5,95E‐06    PRDM8  ‐1,41E+00  4,40E‐03 
PDE10A  ‐1,34E+00  6,34E‐06    KDM5B  ‐7,20E‐01  4,41E‐03 
TMEM62  ‐1,08E+00  6,90E‐06    CFHR3  ‐1,94E+00  4,96E‐03 
CXCL16  ‐1,04E+00  6,90E‐06    BOK  ‐8,75E‐01  3,86E‐02 
TMEM87A  ‐9,99E‐01  6,90E‐06    RPRM  ‐2,93E+00  3,39E‐02 
PARD3B  ‐6,86E‐01  3,85E‐02    ZFP36  ‐8,59E‐01  4,98E‐03 
SPTAN1  ‐9,51E‐01  1,04E‐05    DMRTA2  ‐1,63E+00  5,04E‐03 
ADAL  ‐1,00E+00  1,21E‐05    ACVR1C  ‐1,54E+00  5,04E‐03 
ANKRD1  ‐1,48E+00  1,22E‐05    APOLD1  ‐7,64E‐01  1,27E‐02 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MNS1  ‐1,42E+00  1,22E‐05    GPM6A  ‐9,38E‐01  5,19E‐03 
CLVS2  ‐2,37E+00  1,27E‐05    WSCD1  ‐9,60E‐01  1,78E‐02 
YPEL5  ‐6,88E‐01  4,16E‐02    C8orf42  ‐1,21E+00  2,97E‐02 
NME5  ‐2,31E+00  1,49E‐05    SLC2A10  ‐7,82E‐01  5,45E‐03 
LPL  ‐2,24E+00  1,57E‐05    FCGRT  ‐7,50E‐01  5,46E‐03 
PTGFR  ‐1,26E+00  1,28E‐02    RPH3AL  ‐8,94E‐01  1,23E‐02 
AS3MT  ‐1,03E+00  1,57E‐05    TMSB15A  ‐7,33E‐01  5,59E‐03 
LRP1  ‐5,99E‐01  3,92E‐02    RFX6  ‐1,86E+00  5,82E‐03 
G0S2  ‐1,86E+00  2,14E‐05    PLXNA4  ‐3,00E+00  5,83E‐03 
BEND5  ‐2,59E+00  2,24E‐05    ARHGEF17  ‐7,69E‐01  5,83E‐03 
LSR  ‐9,72E‐01  2,31E‐05    ABAT  ‐6,44E‐01  4,01E‐02 
POR  ‐6,02E‐01  3,14E‐02    DSCR6  ‐7,45E‐01  1,81E‐02 
AC010336.1  ‐1,47E+00  2,63E‐05    HAUS2  ‐7,12E‐01  5,85E‐03 
TMSB4X  ‐1,40E+00  3,06E‐05    NUDT14  ‐6,64E‐01  3,52E‐02 
ZSCAN29  ‐9,39E‐01  3,23E‐05    RIMS1  ‐2,71E+00  6,11E‐03 
EPSTI1  ‐1,61E+00  3,63E‐05    LSAMP  ‐4,01E+00  6,19E‐03 
STARD8  ‐7,44E‐01  3,39E‐02    FGF12  ‐2,50E+00  6,59E‐03 
BASP1  ‐2,88E+00  3,80E‐05    ZNF467  ‐1,30E+00  6,88E‐03 
PGPEP1  ‐6,14E‐01  3,65E‐02    TCN2  ‐2,76E+00  2,35E‐02 
PLXNA3  ‐6,54E‐01  1,52E‐02    HS6ST3  ‐1,72E+00  1,00E‐02 
GANC  ‐1,04E+00  3,80E‐05    METTL7A  ‐7,81E‐01  4,32E‐02 
TP53INP1  ‐9,90E‐01  4,09E‐05    HOXA4  ‐1,02E+00  7,00E‐03 
LGALS3  ‐8,44E‐01  1,48E‐02    RAB9B  ‐8,09E‐01  7,00E‐03 
LRRTM4  ‐1,73E+00  4,57E‐05    PAK3  ‐1,42E+00  7,34E‐03 
ITGB4  ‐9,06E‐01  1,80E‐02    CAV1  ‐9,22E‐01  7,39E‐03 
LYPD6  ‐9,44E‐01  4,62E‐05    SPOCK3  ‐1,44E+00  7,44E‐03 
INADL  ‐6,00E‐01  4,51E‐02    ALG1L  ‐9,00E‐01  4,33E‐02 
MTMR11  ‐1,30E+00  5,23E‐05    SLC35F1  ‐6,26E‐01  2,54E‐02 
APOBEC3B  ‐1,69E+00  5,41E‐05    PARD6A  ‐1,06E+00  7,91E‐03 
SORT1  ‐5,46E‐01  4,57E‐02    ARHGAP33  ‐7,68E‐01  8,02E‐03 
FBXO27  ‐1,03E+00  5,90E‐05    GALNT3  ‐3,05E+00  8,19E‐03 
AHRR  ‐9,02E‐01  5,96E‐05    GMCL1  ‐7,08E‐01  8,21E‐03 
EDNRB  ‐4,91E+00  4,40E‐02    LGR5  ‐8,71E‐01  8,42E‐03 
MIXL1  ‐1,78E+00  5,96E‐05    DTX3L  ‐7,66E‐01  8,46E‐03 
LRRC57  ‐9,43E‐01  8,24E‐05    CHSY3  ‐7,78E‐01  4,03E‐02 
SLC22A23  ‐6,19E‐01  3,00E‐02    KIAA1539  ‐8,79E‐01  8,66E‐03 
SPTB  ‐1,16E+00  9,61E‐05    MT1F  ‐1,20E+00  1,43E‐02 
PLD5  ‐3,79E+00  1,09E‐04    PTPRO  ‐1,65E+00  8,72E‐03 
TCP11L2  ‐1,09E+00  1,12E‐04    LHX9  ‐1,15E+00  8,86E‐03 
KCTD12  ‐9,23E‐01  1,22E‐04    C2orf72  ‐7,59E‐01  1,80E‐02 
SLC44A5  ‐6,15E‐01  3,26E‐02    MICB  ‐7,71E‐01  4,01E‐02 
CYP1B1  ‐2,21E+00  2,18E‐02    RET  ‐9,22E‐01  8,86E‐03 
PVALB  ‐1,98E+00  1,22E‐04    GFRA1  ‐1,14E+00  8,91E‐03 
HOXA6  ‐1,69E+00  1,28E‐04    TMEM200C  ‐1,58E+00  1,02E‐02 
DKK3  ‐1,38E+00  1,59E‐04    DDAH2  ‐7,29E‐01  1,78E‐02 
FRAS1  ‐6,65E‐01  1,50E‐02    HOXA3  ‐9,18E‐01  9,12E‐03 
SLC38A4  ‐1,64E+00  1,12E‐02    PRKCH  ‐7,96E‐01  9,13E‐03 
IFI27L2  ‐9,44E‐01  1,59E‐04    TP73  ‐6,94E‐01  9,41E‐03 
SNAP23  ‐8,66E‐01  1,59E‐04    KIAA0913  ‐5,64E‐01  4,75E‐02 
FAM105A  ‐8,49E‐01  2,48E‐04    RP11‐428C6.1  ‐9,18E‐01  2,47E‐02 
OTX2  ‐1,28E+00  2,58E‐04    KCNT2  ‐2,07E+00  9,69E‐03 
CACNA2D3  ‐1,04E+00  2,63E‐04    ATXN1L  ‐5,93E‐01  2,39E‐02 
FREM2  ‐9,02E‐01  2,78E‐04    EPPK1  ‐2,12E+00  3,39E‐02 
IQGAP1  ‐6,55E‐01  1,39E‐02    PCDHGC4  ‐1,51E+00  2,24E‐02 
SECTM1  ‐1,68E+00  1,11E‐02    PRR16  ‐1,11E+00  9,98E‐03 




Table  S  5:  List  of  significantly  (p<0.05)  up‐regulated  transcripts  in  HEK‐miR‐155  TL 
compared to the TL of HEK‐vector (n= 121).  
Gene  Log2‐FC  P‐value    Gene  Log2‐FC  P‐value 
FAM78A  2,13E+00  1,38E‐23    PALM2  1,01E+00  1,02E‐02 
TNFRSF11B  5,53E+00  1,36E‐19    GABRD  9,54E‐01  1,10E‐02 
DPYSL3  1,98E+00  1,94E‐19    FAM91A1  6,37E‐01  1,16E‐02 
CCND1  4,19E+00  1,96E‐12    EFR3A  6,42E‐01  1,17E‐02 
ZNF813  2,02E+00  4,35E‐12    CAMKV  7,14E‐01  1,26E‐02 
KCNQ2  1,32E+00  1,88E‐10    WDR67  6,47E‐01  1,30E‐02 
ALDH1A2  1,24E+00  1,71E‐09    UTP23  6,45E‐01  1,33E‐02 
FAM84B  1,09E+00  1,04E‐07    ZNF44  8,38E‐01  1,38E‐02 
CA12  1,14E+00  6,92E‐07    TEX15  6,45E‐01  1,54E‐02 
NDRG1  1,19E+00  1,95E‐06    SEH1L  6,25E‐01  1,56E‐02 
ZNF85  2,18E+00  3,35E‐06    PCDH19  8,58E‐01  1,62E‐02 
PROCR  1,04E+00  1,09E‐05    PPID  6,26E‐01  1,74E‐02 
EDA2R  3,78E+00  1,46E‐05    CACYBP  6,22E‐01  1,78E‐02 
ADCYAP1R1  9,74E‐01  1,62E‐05    TNFRSF10D  6,87E‐01  1,87E‐02 
POLR3G  1,14E+00  2,24E‐05    C4orf43  6,09E‐01  1,96E‐02 
BMP2  1,83E+00  2,51E‐05    ADA  6,85E‐01  2,00E‐02 
C19orf51  9,74E‐01  4,40E‐05    ZNF586  8,54E‐01  2,00E‐02 
ATP1A3  9,36E‐01  5,23E‐05    DSCC1  5,93E‐01  2,00E‐02 
HMOX1  1,05E+00  6,45E‐05    MT1X  7,22E‐01  2,04E‐02 
LY6E  8,72E‐01  9,48E‐05    TRIB1  1,20E+00  2,04E‐02 
BEND4  9,23E‐01  1,10E‐04    CYC1  7,01E‐01  2,14E‐02 
BOP1  9,07E‐01  1,38E‐04    EGLN3  6,74E‐01  2,24E‐02 
TRMT12  8,56E‐01  3,61E‐04    TAP2  6,40E‐01  2,32E‐02 
COTL1  8,24E‐01  5,14E‐04    CHRAC1  6,24E‐01  2,32E‐02 
ZNF256  1,25E+00  5,54E‐04    MMP2  9,21E‐01  2,35E‐02 
MRPL13  8,04E‐01  6,32E‐04    CHRNA4  1,34E+00  2,35E‐02 
EXT1  8,09E‐01  7,92E‐04    C3orf14  6,10E‐01  2,43E‐02 
SPRY1  8,28E‐01  8,33E‐04    BCL6B  6,20E‐01  2,85E‐02 
KLRG2  8,24E‐01  1,22E‐03    NRG2  9,31E‐01  2,95E‐02 
ETV1  1,25E+00  1,57E‐03    WT1  6,78E‐01  2,97E‐02 
DHRS2  1,13E+00  1,61E‐03    NIP7  5,97E‐01  2,99E‐02 
C8orf33  7,39E‐01  2,20E‐03    NEIL2  6,46E‐01  2,99E‐02 
ALPL  8,46E‐01  2,88E‐03    TRIM71  7,61E‐01  2,99E‐02 
ARSJ  9,01E‐01  3,05E‐03    IL12RB2  8,68E‐01  3,08E‐02 
ELOVL6  7,35E‐01  3,53E‐03    TESC  7,78E‐01  3,09E‐02 
ABCE1  6,83E‐01  3,58E‐03    SQLE  5,86E‐01  3,15E‐02 
C12orf35  7,26E‐01  3,62E‐03    SLC24A4  8,73E‐01  3,23E‐02 
FAM150A  1,93E+00  3,67E‐03    LYAR  5,91E‐01  3,23E‐02 
COL14A1  1,28E+00  3,80E‐03    HRSP12  6,01E‐01  3,24E‐02 
DNMT3B  7,34E‐01  3,93E‐03    FBXO41  6,51E‐01  3,24E‐02 
SULT1A1  1,04E+00  3,93E‐03    TOP1MT  5,97E‐01  3,24E‐02 
TATDN1  7,31E‐01  4,06E‐03    TRPS1  5,95E‐01  3,27E‐02 
GPATCH4  7,12E‐01  4,29E‐03    CCT6A  5,69E‐01  3,39E‐02 
SPRED2  7,40E‐01  4,96E‐03    ZNF528  1,63E+00  3,52E‐02 
TERT  1,30E+00  4,98E‐03    NFASC  8,08E‐01  3,55E‐02 
RNF125  7,19E‐01  5,25E‐03    ZC3H15  5,74E‐01  3,55E‐02 
GPRIN3  7,53E‐01  5,34E‐03    PRPS2  5,66E‐01  3,69E‐02 
PYCRL  7,81E‐01  5,43E‐03    NCS1  5,89E‐01  3,74E‐02 
RASGEF1A  7,31E‐01  5,83E‐03    PLCD3  5,85E‐01  3,94E‐02 
THEM4  6,95E‐01  6,45E‐03    PRR5L  8,79E‐01  4,07E‐02 
FBXO32  7,56E‐01  6,97E‐03    ANKRD34A  6,69E‐01  4,20E‐02 
PDZRN3  7,76E‐01  7,48E‐03    ASAP1  5,68E‐01  4,23E‐02 
RAB39  9,65E‐01  7,58E‐03    ADAT2  5,88E‐01  4,28E‐02 
POP1  6,83E‐01  7,91E‐03    ZNF121  6,05E‐01  4,48E‐02 
KHDRBS3  7,12E‐01  8,54E‐03    GCLM  5,55E‐01  4,50E‐02 
SLC11A1  1,49E+00  8,66E‐03    RBFOX3  1,16E+00  4,50E‐02 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Gene  Log2‐FC  P‐value    Gene  Log2‐FC  P‐value 
ETV5  1,85E+00  8,71E‐03    OR2V2  4,11E+00  4,77E‐02 
HSPE1  6,82E‐01  8,99E‐03    FAM196A  1,31E+00  4,78E‐02 
ETV4  2,16E+00  9,60E‐03    C1QBP  5,48E‐01  4,86E‐02 
FAM49B  6,55E‐01  9,91E‐03    EPHA8  1,00E+00  5,00E‐02 
TMEM145  8,37E‐01  1,02E‐02         
 
Table S 6: Summary of mapped and quantified Sequencing reads per sample and replicate 




JEKO‐1  IP AGO2  1  27019022  19411847  71.85 
JEKO‐1  IP AGO2  3  27083054  19320009  71.34 
JEKO‐1  IP IgG1  1  22964967  15850150  69.02 
JEKO‐1  IP IgG1  3  24249235  16848261  69.48 
JEKO‐1  TL  1  36589431  26452402  72.30 
JEKO‐1  TL  3  47718747  34900024  73.14 
MEC‐1  IP AGO2  1  35201658  25259905  71.76 
MEC‐1  IP AGO2  2  28727071  20896781  72.74 
MEC‐1  IP AGO2  3  36410713  26467541  72.69 
MEC‐1  IP IgG1  1  36612969  25650654  70.06 
MEC‐1  IP IgG1  2  32981148  23281289  70.59 
MEC‐1  IP IgG1  3  31578804  21761586  68.91 
MEC‐1  TL  1  48052168  35624017  74.14 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